BMT CTN 0802 
A Multi-Center, Randomized, Double Blind, Phase 
III Trial Evaluating Corticosteroids with 
Mycophenolate Mofetil vs . Corticosteroids with 
Placebo as Initial Systemic Treatment of Acute 
GVHD 
[STUDY_ID_REMOVED] 
-
  
 
A Multi-Center, Randomized, Double Blind, Phase III Trial 
Evaluating Corticosteroids wi th Mycophenolate Mofetil  
vs. Corticosteroids with Plac ebo as Initial Systemic  
Treatment of Acute GVHD 
 
BMT CTN PROTOCOL 0802 
Version 3.0 
 
Study Chair 
Javier Bola√±os-Meade, MD1 
Study co-Chair 
Vincent T. Ho, MD2 
 
Protocol Team 
 
Amin Alousi, MD3 
Joseph Antin, MD2 
Kate Barowski4 
Shelly Carter, ScD4 
James Ferrara, MD5 
Mary Horowitz, MD6 
John Levine, MD5 Margaret MacMillan, MD7 
Paul Martin, MD8 
Marco Mielcarek, MD8 
Brent Logan, PhD6 
Georgia Vogelsang, MD1 
Daniel Weisdorf, MD7 
 
 
Sponsored by [CONTACT_98376], Lung, and Blood Institute 
National Cancer Institute 
 
1 Johns Hopkins University 
2 Dana Farber Cancer Institute 
3 University of [LOCATION_007], MD Anderson Cancer 
Center 
4 The EMMES Corporation  5 University of Michigan 
6 Center for International Blood and Marrow Transplant 
Research, Medical College of Wisconsin 
7 University of Minnesota 
8 Fred Hutchinson Cancer Research Center 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
i Core Study Participants:   Affiliate Study Participants:  
Case Western Reserve University Consortium 
   - Ohio State University     - Oregon Health & Science University    - University Hospi[INVESTIGATOR_98314]    - Washington University, Barnes Jewish Hospi[INVESTIGATOR_110822]    - Brigham & Women‚Äôs Hospi[INVESTIGATOR_307]    - [LOCATION_005] General Hospi[INVESTIGATOR_110823]-Ketteri ng Cancer Center 
Pediatric Bone and Marrow Transplant    - Children‚Äôs Healthcare of Atlanta    - Children‚Äôs Medical Center of Dallas    - Children‚Äôs Memorial - Northwestern    - Hackensack University Medical Center    - Levine Children‚Äôs Hospi[INVESTIGATOR_307]    - Medical University of South Carolina    - Nationwide Children‚Äôs Hospi[INVESTIGATOR_307] 
   - OHSU, Doernbecher Children‚Äôs Hospi[INVESTIGATOR_307] 
   - Penn State College of Medicine    - Roswell Park Cancer Institute, Pediatric BMT    - UCLA, Mattel Children‚Äôs Hospi[INVESTIGATOR_307]    - University of Alabama at Birmingham    - University of Mississippi [INVESTIGATOR_60584]    - University of North Carolina at Chapel Hill    - University of Utah/ Primary Children‚Äôs Medical 
Center 
Stanford Hospi[INVESTIGATOR_110824], San Diego Medical Center 
University of [LOCATION_012] College of Medicine University of Michigan Cancer Center University of Minnesota  University of Pennsylvania University of [LOCATION_007], MD  Anderson Cancer Center 
  Avera Hematology & Transplant Center 
Banner Research Institute Baylor University Medical Center Beth Israel Deaconess Medical Center Blood & Marrow Transplant Program at 
Northside Hospi[INVESTIGATOR_110825] & Clinics Utah BMT/ University of Utah Medical 
School 
Virginia Commonwealth University, 
MCV Hospi[INVESTIGATOR_110826] ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
ii PROTOCOL SYNOPSIS ‚Äì BMT CTN PROTOCOL 0802 
 
A Multi-Center, Randomized, Double Blind, Ph ase III Trial Evaluating Corticosteroids 
with Mycophenolate Mofetil vs. Corticostero ids with Placebo as Initial Systemic  
Treatment of Acute GVHD 
 
Principal Investigator:  [INVESTIGATOR_110827]√±os Meade, MD 
Co-Principal Investigator: [CONTACT_85006] T. Ho, MD 
 Study Design:  The study is a Phase III, ra ndomized double blind, placebo 
controlled trial evaluating the addition of MMF vs. placebo to 
systemic corticosteroids as initial therapy for acute GVHD.  The primary endpoint will be GVHD free survival at Day [ADDRESS_123451] been used  as primary therapy for acute 
GVHD for many years.  Historical  published and unpublished data 
from Johns Hopkins, M. D. Anderson, University of Michigan and others defined an expected 35%- 53% complete response (CR) at 
Day +[ADDRESS_123452] rates of 
CR at Day 28 and overall survival, supporting its evaluation in a Phase III study.  Day 56 GVHD-free survival for the four treatment arms (all combining corticosteroids with one of the four study drugs) ranged from 39-71% across the four study arms. 
 In this trial, patients with  newly diagnosed acute GVHD will 
receive corticosteroids and will be randomized to also receive 
either placebo or mycophenolat e mofetil.  Each arm will be 
assessed for safety (stoppi[INVESTIGATOR_110828]) and efficacy. 
 Primary Objective:  The primary objective is to estimate graft-versus-host disease free 
survival (acute or chronic) at  Day 56 after randomization without 
additional therapy. 
 Secondary Objectives:  Secondary objectives include: 
1. Proportions of complete, partia l (PR), mixed response, no 
response and progression among su rviving patients at Day 14, 
28 and 56.  
2. Treatment failure (treatment fa ilure defined as: no response, 
progression, administration of a dditional therapy for GVHD, or 
mortality) at Day 14, 28, and 56. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
iii 3. The incidence of acute GVHD flare after CR/PR requiring 
additional agent (including 2.5 mg /kg/day of prednisone [or 
methylprednisolone e quivalent of 2 mg/kg/ day]) for systemic 
therapy before Day [ADDRESS_123453]-randomization.   
4. Incidence of discontinuation of immune suppression without 
acute GVHD flare and without di sease progression/recurrence 
by [CONTACT_52996] 56, 180, and [ADDRESS_123454]-randomization. 
6. Incidence of topi[INVESTIGATOR_2855]/non-absorb able therapy given by [CONTACT_2006] 56. 
7. Incidence of chronic GVHD by [ADDRESS_123455] randomization. 
12. Non-relapse mortality at 6 and 12 months. 
13. Change in patient-reported outcomes from enrollment to Day 
56. 
 Eligibility:  Patients must have acute GVHD (grade I-IV) requiring systemic 
therapy.  No previous systemic immune suppressive therapy for 
acute GVHD is allowed except for a maximum [ADDRESS_123456] an absolute neutrophil count (ANC) greater than 500/ ŒºL.  Patients with acute 
GVHD after salvage donor lymphocytes are not eligible (preplanned DLI is allowed).  
 Treatment Description:  All patients will receive prednisone 2 mg/kg/day PO (or 
methylprednisolone at 1.6mg/kg/ day IV) divided in 1-2 daily 
doses.  Prednisone may be tape red as tolerated according to 
institutional practice.  However, prednisone taper may not start 
sooner than 3 days after randomi zation, and the prednisone dose 
can not be less than 0.25 mg/kg/day prednisone (methylprednisolone 0.2 mg /kg/day) at Day [ADDRESS_123457]-
randomization.   
 Patients will be randomized in a 1:1 fashion to receive either 
placebo or mycophenolate mofetil 1 gm  PO or IV every 8 hours.  
Study drug (MMF/Placebo) should be  discontinued by [CONTACT_2006] 56, or 
when prednisone taper is comp lete, whichever occurs first.  
 Patients developi[INVESTIGATOR_110829] (e.g. 
calcineurin inhibitor, sirolimus, etc.) should have their prophylaxis 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
iv medication continued during th e study period if possible.  
Concurrent or addition of topi[INVESTIGATOR_110830] (skin creams, oral 
beclomethasone, and other non-abso rbable steroids) is allowed. 
 In addition to prescribed study drug plus corticosteroids, all 
patients should receive transf usion support per institutional 
practice; anti-infective prophylax is against herpes viruses, 
Pneumocystis jiroveci, bacterial and fungal infections should be 
followed according to institutional practices.  Pre-emptive monitoring and treatment st rategy for CMV is strongly 
recommended. 
 GVHD organ stage scores, overall clinical grade, biopsy 
information for GVHD, GVHD medi cations, presence of chronic 
GVHD, and steroid dose will be recorded weekly and reported to the BMT CTN Data Coor dinating Center (DCC). 
 Accrual Objective:  [ADDRESS_123458] udy arm (a total of 372 patients). 
 Accrual Period:  The estimated accrual period is 3 years. 
 Study Duration: Patients will be followed for 12 months following initiation  of 
therapy.  
  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
v STUDY SCHEMA 
 
Aim:  To determine if the addition of mycophenolate mofetil to corticosteroids as initial therapy for acute 
GVHD improves GVHD free survival and overall clinical outcome.  
 
Inclusion Criteria 
1. Acute GVHD diagnosed after allogeneic 
hematopoietic stem cell transplant using either bone marrow, PBSC or cord blood.  
2. Acute GVHD developi[INVESTIGATOR_110831]-planned DLI is 
eligible. 
3. Grade I-IV acute GVHD requiring systemic 
therapy. 
4. Patients of all ages will be included. 
5. Biopsy confirmation of GVHD is recommended, 
but not required.  Enrollment should not be delayed awaiting biopsy or pathology results.   
6. The patient must have received no previous 
systemic immune suppressive therapy for treatment  of acute GVHD, except for a maximum 
72 hours of prior corticosteroid therapy  
7. Clinical status at enrollment to allow tapering of  
prednisone to not less than 0.25 mg/kg/day 
prednisone (0.2 mg/kg/day methylprednisolone) at 
Day 28 of therapy  
8. ANC greater than 500/ ŒºL. 
9. Signed informed consent and/or assent. 
10. Assent and educational materials provided to, and 
reviewed with, patients under the age of 18. Exclusion Criteria 
1. Mycophenolate mofetil or mycophenolic acid 
(Myfortic) given within 7 days of enrollment. 
2. Active uncontrolled infection. 
3. Relapsed/persistent malignancy requiring rapid 
immune suppression withdrawal. 
4. Patients that have undergone an unscheduled (or not 
part of original transplant therapy plan) DLI. 
5. Patients unlikely to be available at the transplant 
center on Day 28 and 56 of therapy. 
6. A clinical syndrome resembling de novo chronic 
GVHD developi[INVESTIGATOR_110832]. 
7. Other drugs for GVHD treatment 
8. If any prior steroid therapy (for indication other than 
GVHD), treatment at doses > 0.5 mg/kg/day methyl-prednisolone within [ADDRESS_123459] normalized bilirubin by 
[CONTACT_2006] 56. 
13. Patients with a history of intolerance/allergy to 
MMF.  
 
After 3 days of full dose corticosteroids + MMF/placebo : Taper steroids as tolerated according to institutional 
practices, but to no less than 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone) on Day 28.  Steroid 
taper may not start sooner than 3 days after randomizatio n if GVHD is improving.  Improvement is defined as any 
clinically recognizable lessening of skin  rash, redness, or extent; lessening of diarrhea or lowered bilirubin (though it 
does not have to be greater than or equal to one stage improvement in any involved organ), without worsening in any organ.  
If acute GVHD progresses within 5 days or no response within 14 days, then treat with alternative systemic 
secondary GVHD therapy at the physician‚Äôs discretion.  This patient would be considered a failure for the primary 
endpoint.  This patient will be considered ‚Äúoff study tr eatment‚Äù, but will remain on study to be followed for study 
endpoints.    
If acute GVHD flares during taper of prednisone, steroid dosing may be re-escalated or secondary therapy 
added at the discretion of the treating physician.  Re-escalation of steroid for GVHD flare alone will not be 
considered as treatment failure. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
vi STUDY SCHEMA (cont‚Äôd) 
 
Suggested  prednisone taper for responders (round 
to nearest 5 mg of prednisone): 
2 mg/kg/day once or twice a day Days 1-5. 
1.5 mg/kg/day once daily Days 6-10. 
1 mg/kg/day Days 11-15. 
0.5 mg/kg/day Days 16-20 
0.25 mg/kg/day Days 21-28 (prednisone may be 
tapered as tolerated to no less than 0.25 mg/kg/day (methylprednisolone 0.2 mg/kg/day) at Day 28.  Then taper according to institutional guidelines.  The goal is to get to < 0.2 mg/per/kg per day of 
prednisone or < 0.16 mg/per/kg per day of 
methylprednisolone by [CONTACT_2006] 56. Primary endpoint: 
- Acute and chronic GVHD free survival at Day 56 
after randomization. 
Secondary endpoints: 
- Proportion of CR, PR, mixed response, no response 
and progression, among surviving patients at Days 14, 28 and 56. 
- Treatment failure (defined as no response, 
progression, administration of additional therapy fro GVHD, or mortality) at Days 14, 28, and 56. 
- Incidence of acute GVHD flares after CR/PR 
requiring additional agents 
(including 2.5 mg/kg/day 
of prednisone [or methylprednisolone equivalent of 2 
mg/kg/day]) for systemic therapy before Day 56. 
- Incidence of discontinuation of immune suppression 
without acute GVHD flare and without disease progression/recurrence by [CONTACT_52996] 56, 180, and [ADDRESS_123460]-therapy. 
- Steroid dose at Day 28 and Day 56.  
- Incidence of topi[INVESTIGATOR_2855]/non absorbable therapy at Day 
56. 
- Incidence of Chronic GVHD by [ADDRESS_123461] 
randomization. 
- Change in patient-reported outcomes from enrollment 
to Day 56.
 
 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
vii STUDY DESIGN SCHEMATIC 
 
  
                    Primary Endpoint: 
Proportion of patients surviving at Day [ADDRESS_123462] bo and corticosteroids 
at 2 mg/kg prednisone/day PO or IV equivalent in 
methylprednisolone (1.6 mg/kg) 
Continue to enroll until [ADDRESS_123463] been 
recruited to 186 patients per arm 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
viii TABLE OF CONTENTS 
 
1. BACKGROUND AND RATIONALE ......................................................................... 1-1  
1.1. Acute Graft-vs.-Hos t Disease ........................................................................................ 1-1  
1.2. Primary Therapy for Acute GVHD ............................................................................. 1-1  
1.2.1.  Mycophenolate Mofetil/Placebo ................................................................................. 1-5  
2. STUDY DESIGN ............................................................................................................ 2-1  
2.1. Study Design .................................................................................................................. . 2-1  
2.2. Primary Objective and Ration ale for Study Design ................................................... 2-1  
2.3. Eligibility ................................................................................................................... ...... 2-1  
2.3.1.  Inclusion Criteria ......................................................................................................... 2- 1 
2.3.2.  Exclusion Criteria........................................................................................................ 2-2  
2.3.3.  Informed Consent ........................................................................................................ 2-3  
2.4. Treatment Plan............................................................................................................... 2 -3 
2.4.1.  Randomization ............................................................................................................ 2-3  
2.4.2.  Corticosteroid Dosi ng and Taper ................................................................................ 2-3  
2.4.3.  MMF/Placebo Formulation, Dosing, and Duration .................................................... 2-4  
2.5. Toxicities and Guidelines for Dose Reduction/Withholding Study Drug ................. 2-6  
2.6. Unblindi ng .................................................................................................................... .. 2-7  
2.7. GVHD Progression or  Non-response ........................................................................... 2-7  
2.8. Acute GVHD Flare ........................................................................................................ 2-7  
2.9. Supportive Care Guidelines .......................................................................................... 2-8  
2.10.  GVHD Scoring ............................................................................................................... 2- 8 
2.11.  Chronic GVHD............................................................................................................. 2-10  
2.12.  Studies of GVHD Biology ............................................................................................ 2-10  
3. STUDY ENDPOINTS .................................................................................................... 3-1  
3.1. Primary Endpo int .......................................................................................................... 3-1  
3.1.1.  Staging and Grading of Acute GVHD ........................................................................ 3-1  
3.2. Secondary Endpo ints ..................................................................................................... 3-1  
3.2.1.  Proportion of CR, PR, MR, NR and Progression ........................................................ 3-2  
3.2.2.  Proportion of Primary Tr eatment Failures .................................................................. 3-2  
3.2.3.  GVHD Flares Requiring Additional Therapy ............................................................. 3-2  
3.2.4.  Immunosuppression Discontinuation .......................................................................... 3-2  
3.2.5.  Steroid Dose at Days 28 a nd 56 after Randomization ................................................ 3-2  
3.2.6.  Incidence of Topi[INVESTIGATOR_2855]/Non-absorbab le Therapy by [CONTACT_2006] [ADDRESS_123464]-randomization ................................. 3-3  
3.2.13.  Change in Patient-reporte d Outcomes from Enrollment to Day 56 ............................ 3-3  
4. PATIENT ENROLLMENT AND EVALUATION .................................................... 4-1  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
ix 4.1. Enrollment and Randomization ................................................................................... 4-1  
4.1.1.  Randomization ............................................................................................................ 4-1  
4.2. Study Monitoring ........................................................................................................... 4- 1 
4.2.1.  Follow-up Schedule .................................................................................................... 4-1  
4.2.2.  Assessments ................................................................................................................ 4- 3 
4.2.3.  Weekly GVHD Monitoring......................................................................................... 4-5  
4.2.4.  Serious Adverse Event (SAE) Reporting .................................................................... 4-5  
4.2.5.  Study Drug Dose Reduction Monitoring .................................................................... 4-5  
4.3. Discontinuation Criteria ................................................................................................ 4-5  
5. Statistical Considerations .............................................................................................. 5-1  
5.1. Study Design .................................................................................................................. . 5-1  
5.1.1.  Accrual ....................................................................................................................... . 5-1  
5.1.2.  Randomization ............................................................................................................ 5-1  
5.1.3.  Primary Endpoint ........................................................................................................ 5-1  
5.1.4.  Primary Hypothesis ..................................................................................................... 5-1  
5.2. Sample Size and Power Considerations ....................................................................... 5-1  
5.3. Interim Analysis and Sto ppi[INVESTIGATOR_130] .................................................................. 5-2  
5.3.1.  Interim Analysis for Efficacy and Futility .................................................................. 5-2  
5.3.2.  Operating Characteristics  of the Design ..................................................................... 5-3  
5.3.3.  Guidelines for Safety Monitoring ............................................................................... 5-4  
5.3.4.  Safety Analysis ........................................................................................................... 5-5  
5.3.5.  Monitoring Guidelines for Dose Reduction ................................................................ 5-5  
5.4. Demographic and Baseline  Characteristics ................................................................. 5-6  
5.5. Analysis of Seconda ry Endpoints ................................................................................. 5-6  
5.5.1.  Proportion of CR, PR, MR, NR and Progression ........................................................ 5-6  
5.5.2.  Proportion of Primary Tr eatment Failures among Su rviving Patients ........................ 5-6  
5.5.3.  GVHD Flares Requiring Additional Therapy ............................................................. 5-7  
5.5.4.  Immunosuppression Discontinuation .......................................................................... 5-7  
5.5.5.  Steroid Dose at Days 28 a nd 56 after Randomization ................................................ 5-7  
5.5.6.  Incidence of Topi[INVESTIGATOR_2855]/Non-absorbab le Therapy by [CONTACT_2006] [ADDRESS_123465]-randomization ................................. 5-8  
5.5.13.  Change in Patient-Repor ted Outcomes from Enrollment to Day 56........................... 5-8  
 
  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123466] STATISTIC FOR 
CENSORED EXPONENTIAL DATA 
APPENDIX E M.D. ANDERSON SYMPTOM INVENTORY (MDASI) CORE 
ITEMS 
APPENDIX F REFERENCES 
  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123467] disease (GVHD) is the ma jor complication of all ogeneic hematopoietic 
stem cell (HSC) transplantation.
[ADDRESS_123468].  It is belie ved that T-lymphocytes c ontained in the donor graft 
respond in vivo to disparate major (HLA) or  minor (non-HLA) histocompatibility antigens 
expressed by [CONTACT_110871][INVESTIGATOR_110833], initiating a cascade of events leading to the signs and symptoms of acute GVHD.
1   
 The syndrome of acute GVHD includes the followi ng signs and symptoms.  Skin involvement 
(maculopapular exanthem) is usually the first sign.  Lesions may be pruritic  or painful, red to 
violaceous in color, and often involve the palms  and soles. Acute GVHD of the gut may involve 
the stomach, small bowel and colon producing persistent na usea and vomiting or profuse 
diarrhea, intestinal bleeding, crampi[INVESTIGATOR_110834].  Liver GVHD produces 
cholestatic liver injury with  hyperbilirubinemia and, in some  cases, hepatocellular enzyme 
elevations.    The use of cyclosporine (CSA) or tacrolimus (FK) plus short course methotrexate (MTX) has lowered the risk for acute GVHD compared to si ngle agent or other combination therapy, but 
even with these regimens, 35-50% of  patients develop Grade 2-[ADDRESS_123469] served as the primary therapy for acute GVHD for over three decades. 
There is some variability among investigators and transplant center s regarding the optimal 
starting dose of corticosteroids,  particularly in early stage GVHD.  However, a recommended 
initial dose of corticosteroids for moderate to severe (Grade II-IV) acute GVHD accepted in most 
transplant centers is 2 mg/ kg/day of methylprednisolone, or an equivalent steroid.
1, 2, 3  T h e  
response rate to single-agent cortic osteroid therapy, when analyzed  in large retrospective reviews 
is approximately 50%.4, 5  Doses higher than 2 mg/kg/day have not been associated with 
improvement in response rates.6  Despi[INVESTIGATOR_95055],  many patients will experience a 
flare of their GVHD upon steroid taper, and th e durability of response is  often substantially 
lower.  In acute GVHD developi[INVESTIGATOR_110835] d unrelated and related donor transplantation, 
durable remission of acute GVHD with steroid al one were reported in only 24% and 40% of 
patients, respectively.7, 8 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123470] widely studied agent 
in this context is anti-thymocyte globulin (ATG).   Single arm Phase II studies of prednisone + 
ATG as initial therapy of acute GVHD have reported response rates from 67% to 80%.
11, [ADDRESS_123471] to corticosteroids as initial therapy for acute GVHD.  Lee et al randomized 102 patients to  receive the monoclonal anti-CD25 (the IL-2 
receptor alpha chain) antibody, daclizumab (1 mg /kg) on Days 1, 4 and weekly thereafter or 
placebo in conjunction with cortic osteroids.  While response ra tes were similar in both groups 
(53 vs. 51%), survival at 100 days and 1 year was inferior in the steroid + daclizumab group.
14  
A randomized study evaluating BT563 (an antibody ag ainst the IL-2 receptor) also did not 
demonstrate an advantage over placebo wh en combined with prednisone alone.[ADDRESS_123472] bo to methylprednisolone also yielded similar 
clinical results.16  Manifestations of acute GVHD responded more quickly in the 
immunoconjugate arm, but benefits were not durable.  Fina lly, Uberti et al reported a 75% 
response rate in 20 patients with biopsy prove n acute GVHD when etanercept, a recombinant 
TNF-alpha receptor fusion protein capable of ne utralizing TNF, was give n in conjunction with 
corticosteroids with tacrolimus.17  
 Recently, the Blood and Marrow Transplant Clinic al Trials Network completed a multi-center 
randomized, four-arm, Phase II trial (BMT CTN 0302) designed to identify the most promising 
agent for combination with steroids as initial therapy for the treatment of GVHD.
[ADDRESS_123473] 2005 and March 2008, 180 patie nts with newly diagnosed GVHD were randomized to 
receive steroids (2 mg/kg/da y methylprednisolone) plus e ither etanercept, mycophenolate 
mofetil, denileukin diftitox or pentostatin.  The primary objective was to estimate the complete response rate at Day [ADDRESS_123474] steroids alone.  The 
median age of patients was 50 yrs (range, 7.5‚Äì69.9) with 96% > 18 yrs; 39% had AML and 63% 
were male.  The graft was peripheral blood (P B) in 61%, bone marrow (BM) in 25% and cord 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
1-3 blood (CB) in 14%.  Myeloablative conditioning was used for 66% of patients, and 53% of 
patients had unrelated donors.  Forty-four pa tients (24%) received mycophenolate mofetil as 
GVHD prophylaxis and were randomized to 1 of the 3 non-mycophenolate mofetil arms.  
 At enrollment, 68% of patients had grade I-II GVHD; 32% had grade III/IV GVHD.  Fifty-three 
percent of patients had visceral  organ involvement at the time of  enrollment.  The treatment arms 
were balanced except cord blood grafts were mo re common in the denileukin diftitox arm (26%, 
p=0.006); peripheral blood grafts were more co mmon in the etanercept arm (78%, p=0.006); and 
the mycophenolate mofetil arm had more myel oablative transplants (82%, p=0.04).  The 
proportion of complete responses at Day 28 we re: etanercept (26%), mycophenolate mofetil 
(60%), denileukin diftitox (53%) and pentostatin (38%).  Day 56 complete plus partial response 
rates were 59%, 78%, 68%, and 71%, respectively.  Six month chronic GVHD (cGVHD) incidence was: etanercept (21%), mycophenolate mofetil (25%), denileukin diftititox (29%), and pentostatin (24%).  Overall survival at 6 m onths was etanercept (59%), mycophenolate mofetil 
(71%), denileukin diftitox (63%),  and pentostatin (55%), respec tively.  After excluding patients 
who received mycophenolate mofetil prophylaxis , the mycophenolate mo fetil arm still had the 
highest Day [ADDRESS_123475] the addition of my cophenolate mofetil to steroids as initial therapy 
of GVHD. 
  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
1-4 TABLE 1.2:  SUMMARY OF STUDY RESULTS FOR BMT CTN 0302 
Outcome Treatment Arm 
Etanercept (N=46) MMF (N=45) Denileukin Diftitox  (N=47)  Pentostatin (N=42) 
 
Day 28 CR  
12 
(26%) Skin: 12/36 
(33%)  
27 
(60%) Skin: 21/35 
(60%)  
25 
(53%) Skin: 17/35 
(49%)  
16  
(38%) Skin: 14/34 
(41%) 
L.G.I.: 4/12 (33%) L.G.I.: 12/18 
(67%) L.G.I.: 5/14 
(36%) L.G.I.: 7/17 
(41%) 
U.G.I.: 5/10 (50%) U.G.I.: 11/12 
(92%) U.G.I.:10/14 
(71%) U.G.I.: 8/13 
(62%) 
Liver: 2/6  (33%) Liver: 5/7 
(71%) Liver: 3/7 
(43%) Liver: 2/5 
(40%) 
Day 28 CR  
(excl. prior MMF ) 9 (28%) 27 (60%) 15 (48%) 11 (39%) 
Day 28 CR/PR 22 (48%) 35 (78%) 28 (60%) 26 (62%) 
Day 56 CR/PR 27 (59%) 35 (78%) 32 (68%) 30 (71%) 
Day 56 Trea 
tment Fail 12 (26%) 4 (9%) 12 (26%) 13 (31%) 
OS Post-Randomization 
at 6 months 59% 
(95% CI: 43%- 72%) 71% 
(95% CI: 54%- 82%) 63% 
(95% CI: 47%- 76%) 55% 
(95% CI: 38%- 69%) 
OS Post-Randomization at 6 months (excl. prior MMF) 70% 
(95% CI: 51%-83%) 71% 
(95% CI: 54%-82%) 61% 
(95% CI: 40%-76%) 54% 
(95% CI: 33%-71%) 
Cum Incidence of Initial 
D/C of steroids at 9 
months 34% 
(95 % CI: 20%- 48%) 31% 
(95% CI: 17%-45%) 20%  
(95% CI: 8%-32%)  20% 
(95% CI: 8%-33%) 
Cum Incidence Day 56 
Grade 3-5 Toxicity (%) 76% 
(95% CI: 63%-88%) 80%  
(95% CI: 67%-92%) 76% 
(95% CI: 64%-89%) 67%  
(95% CI: 52%-81%) 
Cum Incidence Severe/ Life Threatening/ Fatal Infections at Day 270 47%  
(95% CI: 32%-62%) 44%  
(95% CI: 29%-59%) 58%  
(95% CI: 43%-72%) 56%  
(95% CI: 40%-71%) 
Cum Incidence of acute GVHD Flare 
after CR at Day 90 36% 
(95% CI: 21%- 50%) 28% 
(95% CI: 14%- 41%) 35% 
(95% CI: 21%- 49%) 36% 
(95% CI: 21%- 51%) 
Cum Incidence of cGVHD at Day 180 21% 
(95% CI: 9%- 33%) 25% 
(95% CI: 11%- 39%) 29% 
(95% CI: 15%- 43%) 24% 
(95% CI: 10%- 38%) 
Cum Incidence of Relapse at Day 180 14% 
(95% CI: 3%- 24%) 10% 
(95% CI: 1%- 19%) 9% 
(95% CI: 1%- 19%) 13% 
(95% CI: 2%- 24%) 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
1-5 1.2.1.  Mycophenolate Mofetil/Placebo 
 Pharmacology and Mechanism of Action Mycophenolate mofetil (MMF) is a morpholinoet hyl ester of mycophenolic acid (MPA). A 
product of several penicillium species, MPA po ssesses antibacterial, antifungal, antiviral, 
antitumor and immunosuppressive pr operties.  MMF is a pro-dr ug since the immunosuppressive 
activity is evident only after hydrolysis to MPA.  MMF was developed to enhance the 
bioavailability of MPA.  MPA mediates its  effect by [CONTACT_110872] (IMPDH), an enzyme that catalyz es the oxidation of inosine monophosphate to 
xanthine monophosphate, an interm ediate metabolite in the synt hesis of guanosine triphosphate 
(GTP).  Lymphocytes rely on the de novo purine s ynthesis pathway for the nucleotides necessary 
for DNA synthesis; other cells can also rely on  the salvage pathway.  The action of MPA results 
in the depletion of the nucleotide pool in cell s ynthesis.  An additional mode of action of MPA 
may be that, by [CONTACT_110873], it inhibits re cruitment of leukocytes to  sites of inflammation 
by [CONTACT_110874].  
 MMF in acute GVHD  Mycophenolate mofetil (MMF) is an agent alre ady commonly used as GVHD prophylaxis, or 
treatment of steroid refractory GVHD after allogeneic SCT.  MMF suppresses T cell 
proliferation by [CONTACT_110875] e triphosphate.  Basara 
et al initially reported a 65% res ponse rate in [ADDRESS_123476], and this higher dos ing schedule has been to be well 
tolerated.  Pharmacokinetic studies from the an tecedent phase II trial (BMT CTN 0302), where 
the starting MMF dose was [ADDRESS_123477] furt her shown that an increase in MMF dosing to 
q8Hrs (TID) may be warranted, as described below.  Among the 180 subjects enrolled in the BMT CTN 0302 Acute GVHD Trial from November 2005 to March 2008, 45 subjects were randomized to MMF.  Blood samples for pharmacokinetic 
analyses of mycophenolic acid (MPA, the active metabolite of MMF) were available for [ADDRESS_123478] 2 weeks of treatment.  Although the sample size was small, PK data 
from these patients showed that following dosing at  1 gm BID, 45-59% of the trough levels were 
low (defined as MPA trough <0.5 mcg/mL, or free MPA troughs <15 ng/mL), while < 5% had levels that were considered high.  These results confirm that a sizeable fraction of patients likely 
had under-dosing of MMF on the 1gm BID schedul e.  Analysis of MPA levels with GVHD 
responses in this trial further demonstrated th at trough MPA concentrations affect efficacy.  
Although MPA within the first 2 weeks of treatment  did not appear to influence response at Day 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
1-6 28, MPA total (>0.5 mcg/mL) and free (>15 ng/mL) troughs were associated with higher CR/PR 
at Day 56.    Based in part upon these results, the starting dos e of MMF/placebo in the current proposed trial 
will be 1gm TID.  We believe that  this schedule will insure that  a greater proportion of patients 
will have therapeutically suitabl e drug exposure.  Treating physicia ns will be given discretion for 
reducing the MMF/Placebo dose from TID to BID base on potential toxic ities (Section 2.5), and 
the rates of sustained dose reductions on both arms will be monitored in interim analyses to assure patient safety (see monito ring plan, Section 4.25 and Chapter 5). 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123479] udy arm will include cortic osteroids plus either 
mycophenolate mofetil or placebo.    
Accrual Objective:  [ADDRESS_123480] udy arm (a total of 372 patients).  
 
Accrual Period:  The estimated accrual period is 3 years. 
 Study Duration: Patients will be followed for [ADDRESS_123481] disease free survival (acute or chronic) at Day [ADDRESS_123482] 
toxic of the drugs tested (mycophenolate mofetil, etanercept, pentostatin and denileukin diftitox). 
 2.3. Eligibility 
 2.3.1.  Inclusion Criteria 
 Biopsy of involved tissue is strongly encourage d, but not required for study entry.  The clinical 
diagnosis of acute GVHD requiring systemic ther apy with corticostero ids is necessary for 
enrollment on the trial.  Enrollment and random ization includes commitment to continue both 
steroids and study drug as indicated by [CONTACT_110876]-up 
observations.  If the intention to treat a patient  depends on histologic results, the patient should 
not be enrolled on the BMT CTN [ADDRESS_123483] blood.  Recipi[INVESTIGATOR_16483]-
myeloablative and myeloablative transplants are eligible.   
2. Acute GVHD after planned donor lymphocyte infusion or planned T cell addback are 
eligible. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-2  
3. De novo acute GVHD requiring systemic therap y. GVHD is defined as the presence of 
skin rash and/or persistent nausea, vomiting, a nd/or diarrhea and/or cholestasis presenting 
in a context in which acute GVHD is likely to  occur and where other etiologies such as 
drug rash, enteric infection, or hepatotoxic syndromes are unlikely or have been ruled 
out.  Note that patients with stage I and II  skin only (overall grade I) or isolated upper 
gastrointestinal (GI) involvement are elig ible if the treating physician deems that 
systemic high-dose corticostero id treatment is indicated. 
4. The patient must have had no previous systemic immune suppr essive therapy for 
treatment of acute GVHD except for a maximu m 72 hours of prior corticosteroid therapy 
at >0.5mg/kg/day methylpredni solone or equivalent after the onset of acute GVHD. 
5. Clinical status at enrollment to allow tapering of steroids to not less than 0.25 mg/kg/day 
prednisone (0.2 mg/kg/da y methylprednisolone) at  Day 28 of therapy. 
6. Absolute neutrophil count (ANC) greater than 500/ ŒºL. 
7. Written informed consent and/or assent from patient, parent or guardian. 
8. Documentation that the assent  document and education materi als have been provided to, 
and reviewed with, patients between the ages of 7 and 17. 
9. Patients of all ages are eligible.  
10. Biopsy confirmation of GVHD is  recommended, but not required.  Enrollment should not 
be delayed for biopsy or pat hology results unless these are to be used to decide about 
whether to treat for GVHD.  
 2.3.2.  Exclusion Criteria 
1. Patients receiving mycophenolate mofetil or my cophenolic acid (Myf ortic) within seven 
days of screening for enrollment. 
2. Patients with uncontrolled infections will be excluded.  If a bacterial or viral infection is 
present, patients must be receiving definitive therapy and have no signs of progressing infection for [ADDRESS_123484] 
be receiving definitive syste mic anti-fungal therapy and ha ve no signs of progressing 
infection for 1 week prior to enrollment. 
Progressing infection is defined as hemodynamic instability attributable to sepsis or new 
symptoms, worsening physical signs or radiogr aphic findings attributable to infection.  
Persisting fever without other signs or symp toms will not be inte rpreted as progressing 
infection. 
3. Relapsed/persistent maligna ncy requiring rapid immune  suppression withdrawal. 
4. Patients with GVHD after an unplanned DLI, i.e., DLI that was not part of their original 
transplant therapy plan, or DLI given for trea tment of persistent or recurrent malignancy 
after transplantation. 
5. Patients unlikely to be available at the transplantation center on Day 28 and 56 of 
therapy. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-3 6. A clinical syndrome resembling de novo ch ronic GVHD developi[INVESTIGATOR_110836]. 
7. Patients receiving other drugs for the treatment of GVHD.   
8. Patients receiving methylprednisolone > 0.5 mg/kg/day (or 0.6 mg/kg/day prednisone) 
within 7 days before the onset of acute GVH D.  If steroid therapy has been administered 
for treatment of a non- *9+' UHODWHG FRQGLWLRQ DQG WD SHUHG WR ¬î  PJNJGD\
methylprednisolone (0.6 mg/kg/ day prednisone) for seven or more days before the onset 
of acute GVHD, the patient is eligible.  
9. Patients who are pregnant, breast feeding, or, if  sexually active, unwilling to use effective 
birth control for the duration of the study.  Av ailable evidence and/or expert consensus is 
inconclusive or is inadequate for determining infant risk when used during breastfeeding, 
therefore breast feeding patients are not eligible. 
10. Adults unable to provide informed consent. 
11. Patients on dialysis.   
12. Patients with severe hepa tic VOD or sinusoidal obstruction syndrome who in the 
judgment of the treating physician are not expe cted to have normalized bilirubin by [CONTACT_2006] 
56 after enrollment. 
13. Patients with a history of in tolerance/allergy to MMF. 
 2.3.3.  Informed Consent 
 The informed consent process will begin at recognition of subject eligibility and consent will be obtained per institutional practices before study therapy is initiated. 
 2.4. Treatment Plan 
 2.4.1.  Randomization 
 After registration and enrollment, the study partic ipant will be randomized in a 1:1 fashion to 
receive either MMF or placebo as described in Chapter 5.  
 2.4.2.  Corticosteroid Dosing and Taper 
 All patients enrolled on this  trial will receive steroids at a dos e of prednisone 2mg/kg/day PO (or 
methylprednisolone 1.6 mg/kg/day IV) as therap y of acute GVHD.  Pediatric patients unable to 
take tablets can use oral pre dnisolone solution 2 mg/kg/day.  Steroid taper may follow local 
institutional practice.  However, for those improving, steroid taper may not start sooner than [ADDRESS_123485] not be tapered to  less than 0.25 mg/kg/day 
prednisone (or 0.2 mg/kg/day methylprednisolone) on Day 28 .  
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-4 The following is a suggested  prednisone taper.  
 
Suggested taper for responders 
(2 mg/kg/day prednisone orally=1.6 me thylprednisolone mg/kg/day I.V.)  
 
2 mg/kg/day of prednisone orally (or 1.6 mg/k g/day of methylprednisolone I.V) divided 
once or twice/day Days 1-5  
1.5 mg/kg/day once daily Days 6-10  
1 mg/kg/day once daily Days 11-15  
0.5 mg/kg/day of prednisone once daily Days 16-20  
0.25 mg/kg/day of prednisone once daily Days 21-28 
Patients should be tapered as tolerated to no less than 0.25 mg/kg/day (methylprednisolone 
0.2 mg/kg/day) by [CONTACT_2006] 28.  
Then taper according to institutional guidelines with a goal to reach < 0.2 mg/per/kg per 
day of prednisone or < 0.16 m g/per/kg per da y of meth ylprednisolone b y Day 56. 
 
2.4.3.  MMF/Placebo Formulation, Dosing, and Duration 
 Study treatment (MMF/placebo) shoul d be initiated as soon as possible after randomization.  A 
maximum of 48 hours is allowable.    Formulation and Drug Supply  MMF/Placebo will be obtained by [CONTACT_110877] N/EMMES, and distributed through an 
independent contractor.  Questions regardi ng study drug orders and study drug distribution 
should be directed to the tria l protocol coordinator at EMME S.  MMF/placebo will be provided 
by [CONTACT_110878] 8 weeks.  Oral MMF/placebo is available as 250 mg capsules in bottles of  70 each.  Capsules should be  stored at room temperature.   
 Intravenous: MMF/placebo for intravenous use w ill be supplied as a lyophilized powder.  The 
study drug will be reconstituted by [CONTACT_44579] 5% Dextrose in Water (D5W) into each vial. 
Intravenous MMF/placebo does not contain an antib acterial preservative; therefore, the study 
drug should be prepared under aseptic conditions.  Reconstitute each vial with 14 mL D5W.  
Gently shake vial to dissolve the drug.  Furthe r dilute into D5W for a final concentration of 
6 mg/mL.  Dilute 1-g doses in [ADDRESS_123486] at each ce nter should prepare each dose of drug to avoid errors.  Because of the 
potential teratogenic effects of MMF, pharmacists should follow institutional guidelines for the preparation of similar types of solutions.  At  the completion of the study, unused MMF/Placebo 
study drug should be returned to the study team by [CONTACT_110879].  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-5 The investigator (and/or hospi[INVESTIGATOR_98341]) will ensure that all study drug is stored in a secured 
area under recommended storage conditions and is dispensed by [CONTACT_98390].  All 
study drug will be accounted for on medication inventory sheets. 
 The BMT CTN will be allowed at intervals, and upon request during the study, to check unused 
supplies.  Accounting for the use of supplies w ill be by [CONTACT_110880]'s record of 
supplies received, the dispensing records for the total number of patients enrolled at each center and the unused and returned supplies.  The investigator is responsible for maintaini ng drug accountability records.  Drug accountability 
records will be reviewed during monitoring visits.  Each institution may use their own drug accountability log.  Study drug must be administered onl y to patients enrolled in this study as per 
the protocol.  
 
Dose and Administration  For BMT CTN 0802, the dose of MMF will be different than the one used in 0302.  This is based on the pharmacologic analysis of patients receiving MMF enrolled on BMT CTN 0302.  This 
will insure a substantially greater proportion of patients will have therapeutically suitable drug exposure.  Oral dosing should be delivered in either 250 mg units or identical blinded placebo.   
For those < 40 kg, IV dosing should be within ¬± 10%  of the exact dose.  Intravenous doses are 
infused over a two-hour period.  The study drug capsule may not be opened to administer. 
x Patients who weigh > 60 kg should receive MMF 1 gm PO/IV every 8 hours. 
x Patients who weigh between 40-60 kg shoul d receive 750 mg PO/IV every 8 hours. 
x Patients who weigh <40 kg should receive 20 mg /kg IV or PO (up to 750 mg/kg) every 8 
hours. 
x Patients with ¬î ANC < 1000 at the time of enrollment should receive study drug 
every 12 hours.  Once ANC ¬ï [ADDRESS_123487] 3-7 days of therapy and converted to oral MMF as soon as possible 
after the initial 3-7 days of therapy if oral medications and this limited fluid intake are tolerated.  Duration of Study Therapy  MMF/placebo should be discontinued at Day 56, or when the patient is tapered off steroids, 
whichever occurs earlier.  GVHD Prophylaxis Medications  Medications such as cyclosporine, tacrolimus,  sirolimus (if used as GVHD prophylaxis when 
acute GVHD developed) should be continued at therapeutic doses adjusted as necessary for 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-6 renal, central nervous system (CNS) or ot her toxicity using c onventional ma nagement 
guidelines.  The recommended therapeutic tr ough level of cyclosporine is 200-400 ng/mL 
measured by [CONTACT_110881]; institutional levels for other assays.  The recommended 
therapeutic trough level is 5-15 ng/mL for t acrolimus and 3-12 ng/mL for sirolimus.   
 Topi[INVESTIGATOR_110837] : 
 Topi[INVESTIGATOR_110838], including skin creams or GI non-absorbable steroids are 
allowed and should be used according to institu tional practices.  Use of topi[INVESTIGATOR_110839] a secondary endpoint assessment in this trial. 
 Ancillary/supportive care measures for acute GVHD such as the use of anti-motility agents for 
diarrhea, including octreotide, is allowed at th e discretion of the treating physician.  Use of 
ursodiol to prevent/ reduce gall bladder sludging, or  prevent hepatic transp lant complications is 
also allowed according to institutional guidelines.  2.5. Toxicities and Guidelines for Dose  Reduction/Withholding Study Drug 
 Infection: 
Mycophenolate mofetil is potent im munosuppressive agent.  Its use has been associated with 
increased risks of opportunistic infections.  In  the acute GVHD setting, where corticosteroids and 
the disease itself further compromise the immune system, particular caution must be paid to the risks of additional infections.  See Section 2.[ADDRESS_123488] their study drug held at the attending physician's 
discretion.  Study drug can be reinstituted when  the infection epi[INVESTIGATOR_110840].  Re placement doses must not be given, and administration of the 
study drug should not be extended.  Administra tion of the study drug will be discontinued 
permanently if administration is suspended for more than 14 days . 
 GI toxicity: 
Administration of MMF may produce diarrhea, abdo minal pain, and vomiting.  Gastrointestinal 
bleeding and bowel perforation have also been de scribed infrequently.  If GI toxicity requires 
medication for control of persistent vomiting or diarrhea (not related to GVHD), a dose reduction to twice a day can be instituted or, if symptoms persist and are severe (Grade 3 or 4), the study drug (MMF/placebo) can be stopped for 48-72 hours.  IV MMF can be used in patients 
experiencing severe GI toxicity to avoid stoppi [INVESTIGATOR_11743].  If GI toxicity does not resolve 
within 48-72 hours of stoppi[INVESTIGATOR_35648], then this  toxicity is not likely related to the study 
medication and the drug should be  restarted at the original dos e.  Administration of the study 
drug will be discontinued permanently if administration is suspended for more than 14 days.  The Protocol Chair or co-Chair should be consulte d before discontinuing MMF for GI toxicity.   
 Myelosuppression:   
Use of MMF may be associated with myel osuppression.  If the ANC is less than 1000/ PL, 
MMF/placebo dosing should be reduced to every 12 hour dosing.  2QFH$1&¬ïTKRXU
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-7 dosing should be resumed.  If the ANC is less than 500/ PL, the drug should be discontinued until 
neutrophil recovery occurs, and restarted at q12 h our dosing.  Use of filgrastim or perfilgrastim 
or sarmograstim or discontinuation of other myelosuppressive agents  is allowed.  Administration 
of the study drug will be disconti nued permanently if administrati on is suspended for more than 
14 days . 
 Guidelines for Renal Insufficiency:  
As free MPA exposure has not been  directly correlated with re nal dysfunction, pa tients on renal 
replacement therapy are excluded from entry on this trial.  However, if renal insufficiency (estimated GFR <25) develops or  dialysis is needed after st udy entry, the study drug dose should 
be reduced from every 8 to every 12 hours.  Hepatic Dysfunction:  
No adjustments of MMF/placebo ar e required for liver dysfunction. 
 Other Unexpected Toxicities: 
Study drug may be held for other  CTC v.3 Grade 3-4 toxicities that are considered probably 
related to MMF/study drug (such as severe apthous ulcers, hypogamma globulinemia, red cell 
aplasia) at the discretion of the treating phys ician.  Administration of the study drug will be 
discontinued permanently if administrati on is suspended for more than 14 days . 
 2.6. Unblinding 
 There will be no unblinding or crossover as part of this trial.  Unblinding will be allowed only if 
a critical action is needed, the situation is life -threatening, and the unblinding is deemed to be 
necessary to the patient‚Äôs clinical care.  Pe rmission for unblinding must be obtained from the 
medical monitor of the study. Given that there are no data supporting MMF as the preferred 
second line treatment in patients with inadequate responses to first line treatment, unblinding to 
allow patients to receive MMF as second lin e therapy off study will not be allowed. 
 2.7. GVHD Progression or Non-response 
 
If acute GVHD progresses (new organ involvement  or increased organ specific symptoms 
sufficient to increase the organ stage by [CONTACT_110882]) after at least 5 days of study drug administration, or if there is no response (no reduction in any GVHD organ staging) after [ADDRESS_123489] ug may be discontinued, and the 
patient may be treated with a lternative secondary GVHD therapy at the discretion of the treating 
physician.    2.8. Acute GVHD Flare 
 If acute GVHD flares during taper of prednisone, the dose of steroids may be increased at the 
discretion of the treating physician as long as th is increase is to less than 2.5 mg/kg/day of 
prednisone (or methylprednisolone equivalent of 2 mg/kg/day), as in this case it will be considered adding a ‚Äúnew agent‚Äù and the patient will be scored as a failure.    
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-8 2.9. Supportive Care Guidelines 
 In addition to prescribed study drug plus co rticosteroids, all patients should receive the 
following: 
x Transfusion support per institutional practice 
x Anti-infective prophylaxis against herpes viruses, Pneumocystis jiroveci, bacterial and 
fungal infections should be followed accordi ng to standard institutional practices.   
x Routine CMV antigenemia/viral load testi ng by [CONTACT_110883] (with preemptive ganciclovir or valganciclovir therapy in patients who develop a positive assay, as per institutional guidelines).  CMV testing is recommended weekly through at l east Day +[ADDRESS_123490] to both acute and chronic GVHD (if 
present) will be a crucial aspect of this trial.    Weekly acute GVHD organ stage scores, overall clinical grade, biopsy information for GVHD and relevant differential dia gnosis will be recorded and reported to the DCC.  Organ 
involvement, biopsy informati on, staging, differential diagnos is, and GVHD therapy should be 
documented in the medical record using the BMT CTN GVHD scoring stamp or equivalent (see 
below).  Symptoms of chronic GVHD, if present, will be reported according to the BMT CTN MOP (Chapter 2) and reported on the GVHD symptom record.  A sample acute GVHD data record suggested for use in this trial is shown below. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-9  
Today‚Äôs BMT CTN 0802 Clinical Acute GVHD Assessment 
Today‚Äôs Date  ___________     Patient ID/Name  ________________________________________________     Karnofsky/Lansky __________ __________ 
 
      Codes                 Differential Diagnosis 
     [ADDRESS_123491] VOD Other 
Skin ¬Ü ¬Ü ¬Ü ¬Ü ¬Ü  % body rash:________ ¬Ü  ¬Ü  ¬Ü   ¬Ü    
Lower GI ¬Ü ¬Ü ¬Ü ¬Ü ¬Ü ¬Ü Vol: ______________ ¬Ü  ¬Ü  ¬Ü  ¬Ü  ¬Ü    
Upper GI ¬Ü ¬Ü      ¬Ü  ¬Ü  ¬Ü  ¬Ü  ¬Ü    
Liver ¬Ü ¬Ü ¬Ü ¬Ü ¬Ü  Current bili: _________ ¬Ü  ¬Ü  ¬Ü  ¬Ü  ¬Ü  ¬Ü   
 
Systemic Agents:  ¬Ü CSA ¬Ü Tacrolimus ¬Ü Infliximab ¬Ü Dacluzimab  
 ¬Ü Pentostatin 
¬Ü Prednisone ¬Ü Sirolimus 
¬Ü Methylprednisolone 
 ¬Ü Etanercept 
¬Ü Study Drug 
 ¬Ü Open Label MMF 
¬Ü Ontak  
¬Ü Other 
____________________ 
Topi[INVESTIGATOR_110841] :   Skin topi[INVESTIGATOR_8826]  ¬Ü YES    ¬Ü NO;   Non-absorbed oral steroids (e.g., Budesonide, Entocort)   ¬Ü YES    ¬Ü NO 
Is the patient eating equivalent of one meal/day?    ¬Ü YES    ¬Ü NO     Is the patient having formed stools?    ¬Ü YES    ¬Ü NO 
Does the patient have evidence of chronic GVHD?   ¬Ü YES    ¬Ü NO 
Current study drug (MMF/Placebo) dose: __________g ;  Frequency:  ¬Ü TID,  ¬Ü BID, or  ¬Ü Other __________ ;  Formulation:    ¬Ü PO  or  ¬Ü IV 
 
Current steroid dose:   Prednisone ________ mg/day or ________ mg/kg/day;     Methylprednisolone ________ mg/day or ________mg/ kg/day 
+DVWKHVWHURLGGRVHEHHQLQFUHDVHGWR¬ïPJNJGD\RIS rednisone (or 2 mg/kg/day methylpred)? ¬Ü YES    ¬Ü NO;  if yes, date dose increased ___________ 
  If yes, reason for dose increase: ¬Ü flare for GVHD;  ¬Ü Idiopathic Pneumonia Syndrome (IPS);  ¬Ü other (please specify) __________________________ 
 
Code Definitions: 
Skin: 
0  No rash 
1  Maculopapular rash, < 25% of body surface 
2  Maculopapular rash, 25-50% of body surface 
3  Generalized erythroderma 
4  Generalized erythroderma with bullous formation 
and desquamation Lower GI (Diarrhea): 
0  No diarrhea 
1  ¬îP/GD\RUP/NJGD\  
2  501-1000 mL/day or 10-19.9 mL/kg/day 
3  1001-1500 mL/day or 20-30 mL/kg/day 
4  > 1500 mL/day or > 30 mL/kg/day 
5  Severe abdominal pain with or without ileus, or 
stool with frank blood or melena Upper GI: 
0 No protracted nausea and 
vomiting 
1 Persistent nausea, vomiting 
or anorexia Liver (Bilirubin): 
0  < 2.0 mg/dL 
1  2.1-3.0 mg/dL 
2  3.1-6.0 mg/dL 
3  6.1-1.0 mg/dL 4  > 15.0 mg/dL 
 
Signature ________________________________________    Date ____________                                                                                                              V
ersion 1.0 
 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
2-10 2.11. Chronic GVHD  
 Patients developi[INVESTIGATOR_110842]/symptoms of chr onic GVHD (cGVHD) will have symptoms recorded 
on the cGVHD scoring form at the scheduled follow-up visits. 
 
Definite and Possible Manifestations of Chronic GVHD* 
Organ System Definite manifestations of chronic GVHD Possible manifestations of chronic GVHD 
Skin Scleroderma (superficial or fasciitis), lichen 
planus, vitiligo, scarring alopecia, hyperkeratosis pi[INVESTIGATOR_22785], contractures from skin immobility, nail bed dysplasia Eczematoid rash, dry skin, maculopapular 
rash, hyperpi[INVESTIGATOR_371], hair loss 
Mucous membranes Lichen planus, non-infectious ulcers, corneal 
erosions/non-infectious conjunctivitis Xerostomia, keratoconjunctivitis sicca  
GI tract Esophageal strictures, steatorrhea Anorexia, malabsorption, weight loss, 
diarrhea, abdominal pain 
Liver None Elevation of alkaline phosphatase, 
transaminitis, cholangitis, hyperbilirubinemia 
GU Vaginal stricture, lichen planus Non-infectious vaginitis, vaginal atrophy 
Musculoskeletal/ 
Serosa Non-septic arthritis, myositis, myasthenia, 
polyserositis, contractures from joint immobilization Arthralgia 
Hematologic None Thrombocytopenia, eosinophilia, 
autoimmune cytopenias 
Lung Bronchiolitis obliterans  Bronchiolitis obliterans with organizing 
pneumonia, interstitial pneumonitis 
*From BMT CTN MOP Chapter [ADDRESS_123492] for acute GVHD. The BMT CTN Biomarkers Committee suggested four recently published biomarkers fo r validation.  Paczesny et al screened plasma 
with antibody microarrays for 120 proteins in a discovery set of 42 tran splant patients that 
revealed eight potential biomar kers for diagnostic of GVHD.
28  They then measured by [CONTACT_110884] m 424 transplant patients randomly divided into 
training (n = 282) and validation (n = 142) sets.  Logistic regression analysis of these eight 
proteins determined a composite biomarker panel of four proteins  (interleukin-2-receptor-alpha, 
tumor-necrosis-factor-receptor-1, interleukin-8, a nd hepatocyte growth factor) that optimally 
discriminated patients with a nd without GVHD.  In patients with GVHD, Cox regression 
analysis revealed that the biom arker panel predicted survival i ndependently of GVHD severity.  
The authors suggested that the panel of four biomarkers can confirm the diagnosis of GVHD in 
patients at onset of clinical symptoms of GVHD and provide prognostic in formation independent 
of GVHD severity.  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123493] to each sample collection will be noted.  Remaining plasma sample aliquots will be stored  along with an additional Day 56 plasma sample for future 
biomarker studies.  Additionally, whole bl ood collected from the recipi[INVESTIGATOR_110843] 0 
(representing donor DNA) and buccal swabs for DNA from the recipi[INVESTIGATOR_110844], 
frozen and stored for future GVHD related studies.  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
3-1 CHAPTER 3 
 
 3. STUDY ENDPOINTS 
 3.1. Primary Endpoint 
 The primary endpoint is the proportion of GVHD-fr ee survival; that is, the percent of patients 
surviving at Day 56 after enrollment without acu te or chronic GVHD and without other systemic 
DJHQWVRUHVFDODWLRQRIVWHURLGVWR¬ï 2.5 mg/kg/day of prednisone  [or methylprednisolone 
equivalent of 2 mg/kg/day]) added for treatment of GVHD.  
 3.1.1.  Staging and Grading of Acute GVHD 
 In this study we will classify patients by a modified Keystone grading schema.   
 
TABLE 3.1: STAGING 
 Stage 0 Stage 1 Stage  2 Stage 3 Stage 4 
Skin No rash Rash < 25% 
BSA 25-50% > 50% 
Generalized 
erythroderma Plus bullae and 
desquamation 
Gut Adult:  
< 500 ml/day  
Child: < 10 
ml/kg/day  Adult:  500‚Äì1000 ml/day  
Child: 10 -19.9 
ml/kg/day
 Adult: 1001-1500 ml/day  
Child: 20 ‚Äì 30 
ml/kg/day 
 Adult:  >1500 ml/day  
Child: > 30 
ml/kg/day
 Severe 
abdominal pain +/- ileus, flank blood or melena 
UGI  Severe 
nausea/vomiting    
Liver Bilirubin 
¬îPJGO  2.1-3 mg/dl 3.1-6mg/dl 6.1-15mg/dl >15mg/dl 
 
 3.2. Secondary Endpoints 
 Response Definitions: 
CR is defined as a CIBMTR score of [ADDRESS_123494] had no intervening a dditional therapy for an earlier progression, PR or NR. 
Partial response (PR) is defined as improve ment in one or more organs involved with 
GVHD symptoms without progression in others.   For a response to be scored as PR at Day [ADDRESS_123495] had no intervening additional therapy for an earlier progressi on, PR or no response (NR).   
Mixed response  (MR) is defined as improvement in on e or more organs with deterioration 
in another organ manife sting symptoms of GVHD or development of symptoms of GVHD 
in a new organ.   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123496] one organ withou t any improvement in 
others.   
No response (NR) is defined as absence of any improvement or progression as defined.  
Patients receiving secondary therapy (including need to re-escalate ste URLG GRVH WR ¬ï  2.5 
mg/kg/day of prednisone [or met hylprednisolone equivalent of 2 mg/kg/day]) will be classified 
as non-responders.  3.2.1.  Proportion of CR, PR, MR , NR and Progression 
 Proportion of Complete Response (CR), Partia l Response (PR), Mixed Response (MR), No 
Response (NR) and Progression among surv iving patients at Days 14, 28 and 56:   Scoring of 
CR, PR, MR, NR and progression are in compar ison to the participant‚Äôs acute GVHD status 
(score) on Day 0 of the study.  3.2.2.  Proportion of Primary Treatment Failures 
 Proportion of primary treatment failures am ong surviving patients at Days 14, 28 and 56: No 
response, progression, administrati on of additional systemic ther apy for GVHD (or re-escalation 
RIVWHURLGGRVHWR¬ïPJNJGD\RISUHGQLVRQH or methylprednisolone  equivalent of 2 
mg/kg/day), or mortality by [CONTACT_2006] 14, [ADDRESS_123497] -initiation of treatment will be considered a 
primary treatment failure.  3.2.3.  GVHD Flares Requiring Additional Therapy 
 Flares are defined as any progression of acute GVHD after an initial response (i.e., earlier CR or PR) that requires re-escalation of steroid dosi ng, or initiation of additiona l topi[INVESTIGATOR_110845].  While all ‚Äúflares‚Äù will be captured, only flares that requi re additional systemic therapy 
(that is additional drugs) or re -escalation of steroids to ¬ïPJNJGD\RISUHGQLVRQH> or 
methylprednisolone equi valent of 2 mg/kg/day] will be c ounted as failure for the primary 
endpoint.  The rate of all flares before Day 90 will be examined as a secondary endpoint 
 3.2.4.  Immunosuppression Discontinuation 
 Discontinuation of immunosuppres sion will be assessed by [CONTACT_2006] 56, Day 180 and Day 360.  The 
date of discontinuation of  corticosteroids will be recorded.  In addition, dates for discontinuation 
of all other systemic immunosuppre ssive medications (where app licable), including cyclosporine 
or tacrolimus, sirolimus, etc. for treatment or prevention of acute GVHD will be captured. 
 3.2.5.  Steroid Dose at Days 28 and 56 after Randomization 
 Doses of methylprednisolone w ill be converted to prednisone  equivalents by [CONTACT_110885] 1.25.  Pr ednisone doses for each patient  will be converted to mg/kg. 
The cumulative prednisone dose for each patient at Day 28 will be calculated by [CONTACT_110886] (end of each week‚Äôs dose) for each of th e first four weeks of treatment, divided by [CONTACT_110887] ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
3-3 number of days of survival during this interval.  The prednisone dose for each patient at Day 28 
and Day 56 will be recorded  3.2.6.  Incidence of Topi[INVESTIGATOR_2855]/Non-absorbable Therapy by [CONTACT_2006] 56 
 The proportion of patients using eith er topi[INVESTIGATOR_110846]. 
 3.2.7.  Chronic GVHD 
 Chronic GVHD is defined per the BMT CTN Ma nual of Procedures (MOP) Chapter 2.  The 
incidence of chronic GVHD at 6 and 12 months will be computed for each treatment arm.  3.2.8.  Overall and GVHD-free Survival 
 Overall survival and GVHD-free survival at Days 180 and 360 will be computed for each 
treatment arm.  3.2.9.  Systemic Infections though Day 180 
 All microbiologically documented infecti ons or significant infections requiring 
antibiotic/antifungal therapy occurring within six m onths of initiation of th erapy will be reported 
by [CONTACT_4622], date of onset, and sever ity.  For definitions see the BMT CTN MOP.   
 3.2.10.  Incidence of EBV 
 Participating sites are to collect any incidence of  EBV-associated lymphoproliferative disorder or 
EBV reactivation requiring therapy though Day 360.  3.2.11.  Disease-free Survival at [ADDRESS_123498]-randomization 
 Non-relapse mortality at 6 and 12 months will be computed for each treatment arm.  The events for non-relapse mortality are death due to a ny cause other than relapse of the underlying 
malignancy.  3.2.13.  Change in Patient-reported Outcomes from Enrollment to Day 56 
 Study participants who are able to communicat e in English will self-complete the M.D. 
Anderson Symptom Inventory (MDASI) at enrollme nt prior to randomization and at Day 56 +/- 
7 days.  The MDASI is a 19 item instrument that captures 13 symptoms (0=‚Äúnot present‚Äù to 10=‚Äúas bad as you can imagine‚Äù) and 6 items meas uring interference with life from 0 (‚Äúdid not 
interfere‚Äù) to 10 (‚Äúinterfered completely‚Äù).  See the MDASI in Appendix E.  It provides two 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
3-4 summary scales: symptoms and interference.[ADDRESS_123499] data.  Although the 
MDASI has been psychometrically validated in  8 languages, including Spanish, given the 
exploratory nature of this e ndpoint we will only administer the MDASI to patients who are able 
to communicate in English.  Surveys may not be completed by [CONTACT_110888]. 
 NOTE:  Long-term follow-up of patients on this study will con tinue through routine CIBMTR 
mechanisms.   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
4-1 CHAPTER 4 
 
 4. PATIENT ENROLLMENT AND EVALUATION 
 4.1. Enrollment and Randomization 
 Patients will be registered using the BMT CTN Advantage Electronic Data Capture (EDC).  The following procedures shall be followed: 
1. An authorized user at the clinical center completes the initial screening by [CONTACT_110889] A informa tion (inclusion/exclusion criteria) of the 
Eligibility Form within [ADDRESS_123500] emic therapy of acute GVHD.  
Patients will be randomized to MMF versus placebo in a 1:1 ratio.  Treatme nt should be initiated 
as soon as possible after randomization.  A maximum of 48 hours is allowable. 
 4.2. Study Monitoring 
 4.2.1.  Follow-up Schedule 
 The Follow-up Schedule for scheduled study vi sits is outlined in Table 4.2.1.  A detailed 
description of each of the forms and the procedures required for forms completion and 
submission can be found in the Data Management Handbook and User‚Äôs Guide. 
 Follow-up Assessments : The timing of follow-up visits is ba sed on the date of randomization.  
Following randomization, the Transplant Center can print a Patient Visit Schedule listing target 
dates for assessments.  Weeks 1-8 visits are prim arily for acute GVHD scoring.  The subsequent 
visits are for follow-up reports.  Criteria for Forms Submission : Criteria for timeliness of sub mission for all study forms are 
detailed in the Data Ma nagement Handbook and User‚Äôs Guide.  Forms that are not received at 
the DCC within the specified time will be consid ered delinquent.  Transplant Centers can view 
past due forms via the Web-based data entry system.  A missing form will continue to appear until the form is entered into the DCC‚Äôs master database, or until an exception is granted and 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
4-2 entered into the Missing Form Exception File, as detailed in the Da ta Management Handbook 
and User‚Äôs Guide.  Reporting Patient Deaths:  The Recipi[INVESTIGATOR_110847]-
based data entry system within 24 hours of knowledge of a patient‚Äôs death.  If the cause of death 
is unknown at that time, it need not be recorded at  that time.  However, once the cause of death is 
determined, the form  must be updated.  
 Center for International Blood and Marrow Transplant Research (CIBMTR) Data Reporting:  Centers participating in BMT CTN trials must register pre and post-transplant 
outcomes on all consecutive hemat opoietic stem cell transplants done at their institution during 
their time of participatio n to the Center for International Blood and Marrow Transplant Research 
(CIBMTR).  Registration is done using procedur es and forms of the Stem Cell Transplant 
Outcomes Database (SCTOD).  (N ote: Federal legislation require s submission of these forms for 
all US allotransplant recipi[INVESTIGATOR_840].)  Additionally, CIBMTR pre- and post- transplant Report Forms must also be submitted for all patients enrolle d on this trial according to the randomization 
assigned to the patient at the time of initial registration with the CIBMTR.    
Table 4.2.1  
FOLLOW-UP SCHEDULE  
 
Assessment Time  Target Day
1 
(Days Post-Enrollment)  
1 week 7 days 
2 weeks 14 days 3 weeks 21 days 
4 weeks 28 days 
5 weeks 35 days 6 weeks 42 days 7 weeks 49 days 8 weeks 56 days 
90 days 90 days 
6 months 180 days 
12 months 360 days 
 
1.Target day range = r3 days up for Day 7 (subsequent visits 
through Day [ADDRESS_123501] be scheduled weekly). 
 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123502]-of-care unless identified below by ‚Äú*.‚Äù  Pre-Randomization    
1. Recommended biopsy of involved tissue (this is standard of care, not research) 
2. History and physical exam in cluding height and weight 
3. Pregnancy test (if applicable) 
4. Complete acute GVHD staging and grading in formation including assessments of rash, 
diarrhea, nausea/vomiting, wei ght and liver function tests 
5. CBC with differential, platelet count 
6. Liver function tests (bilirubin, alkaline phos phatase, AST, ALT) plus creatinine 
7. Tacrolimus/cyclosporine level (if applicable) 
8. M.D. Anderson Symptom Inventory at Day 0 (see Appendix E) 
9. (OPTIONAL) Samples for laboratory studies  at Day 0 (see Appendix C).*  Donor 
chimerism results to be recorded for the time nearest sample collection. 
Post-Randomization  
1. Karnofsky or Lansky performance status weekly until Day 56 and at Days 90, 180 and 
360  
2. Complete acute GVHD staging and grading in formation including assessments of rash, 
diarrhea, nausea/vomiting, weight and liver function tests weekly until Day 56, and 3, 6 
and 12 months, creatinine weekly until Day 28, and recommended creatinine on Days 35, 
42, 49, 56, and 3, 6, and 12 months. 
3. Chronic GVHD evaluation (if present) 3, 6 and 12 months 
4. CBC with differential, platelet count weekly until Day 56 
5. Toxicity evaluation weekly until Day 56 
6. Steroid dose weekly until Day 56, and at 3, 6 and 12 months 
7. Study drug (MMF/Placebo) dose and fo rmulation weekly until Day 56 
8. Topi[INVESTIGATOR_110848], weekly until Day 56 
9. (OPTIONAL) Samples for laboratory studies at Days 28 and 56 (see Appendix C).*  
Donor chimerism results to be recorded  for the time nearest sample collection. 
10. Infections requiring therapy up to  [ADDRESS_123503]-transplant lymphoprolif erative disorder (PTLD) through Day 360 
12. M.D. Anderson Symptom Inventory at Day 56 (see Appendix E) 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
4-4 Table 4.2.2  REQUIRED ASSESSMENTS 
 
 
 (Day 0) Days Post Randomization  
 Baseline  7* 14 21 28 35 42 49 56   90** 180*** 360*** 
Suggested biopsy of involved tissue  X             
History and physical exam X            
Pregnancy test (if applicable) X            
Karnofsky/Lansky performance status X X X X X X X X X X X X 
Acute GVHD evaluation X X X X X X X X X X X X 
Chronic GVHD evaluation          X X X 
CBC with differential, platelet count X X X X X X X X X    
Basic chemistry (creatinine) X X X X X X X X- X X X X 
Liver function tests (alkaline phosphatase, bilirubin, 
AST, ALT) X X X X X X X X X X X X 
Toxicity evaluation  X X X X X X X X    
Steroid dose  X X X X X X X X X X X 
Study drug dose X X X X X X X X X    
Optional blood, and serum for ancillary laboratory 
studies (see Appendix C)  X    X    X    
Optional buccal Swab (see Appendix C) X            
M.D. Anderson Symptom Inventory (MDASI) X        X    
Chimerism (% donor)1 X    X    X    
*      +/- [ADDRESS_123504] be scheduled weekl y. 
**    +/- 14 days to allow for scheduling flexibility 
***  +/- [ADDRESS_123505] to each sample collection will be noted. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
4-5 4.2.3.  Weekly GVHD Monitoring  
 GVHD scoring will be performed weekly for 8 weeks from study entry.  Days 0, 28 and 56 (+3 
days) scoring must be performed by [CONTACT_110890].  Evaluations at 
other time points may be performed by [CONTACT_110891]. 
 4.2.4.  Serious Adverse Event (SAE) Reporting 
 
Unexpected, grade 3-5 adverse events (AE) will be reported through an expedited AE reporting system 
via AdvantageEDC.  Unexpected, grade 4-[ADDRESS_123506] be reported within three business days of knowledge of the event.  Unexpected, grade 3-5 AEs will be reported usi ng NCI‚Äôs Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.0.  Expected AEs will  be reported using NCI‚Äôs Common Terminology 
Criteria for Adverse Events (CTCAE ) Version 3.[ADDRESS_123507] will receive summary reports of all Grade 3-5 unexpected adverse experiences on an annual basis.  4.2.5.  Study Drug Dose Reduction Monitoring 
 Because the dosing schedule of MMF in this trial will be more frequent (q8hrs) compared to the 
previous phase II trial, additional monitoring for potential toxicity will be implemented.  Patients who are felt to have potential t oxicity related to the study drug (MMF/Placebo) may have their 
dosing reduced from TID to BID dosing at the discretion of the treating physician as outlined in Section 2.5.  The dose and schedule of MMF/place bo will be recorded weekly.  After [ADDRESS_123508] 1 week wit hout re-escalation of dose.  If the incidence of 
sustained dose reduction in the MMF arm is >30% higher than that observed in the placebo arm, 
the protocol team will consult with the Data  and Safety Monitoring Board and consider 
amending the starting MMF/placebo dose to  BID dosing for the entire study.  
 4.3. Discontinuation Criteria 
 Study drug therapy (MMF or placebo) shall be di scontinued and not re-ins tituted if any one of 
the following criteria is met.  The patient will be  taken off study drug therapy at that point, but 
still followed for primary and secondary study endpoint s.  A response assessme nt will be made at 
the time of therapy discontinuation and at subseq uent defined study endpoints.  The patient will 
not be replaced on study.  Note: though the study drug will be discontinued in the following circumstances, corticosteroid dosing will be managed as clinically indicated by [CONTACT_1963].  Follow-up data will be  required unless consent for data collection is withdrawn: 
x Additional systemic GVHD therapy is added for disease progression or non-response 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
4-6 x Steroid dose is HVFDODWHG WR ¬ï  2.5 mg/kg/day of prednis one (or methylprednisolone 
equivalent of 2 mg/kg/day) for disease progression or non-response 
x Development of toxicity that requires withholding of study medication for more then 14 
days (see Section 2.5 for details of dose modifications for toxicity) 
  
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
5-1 CHAPTER 5 
 
 5. STATISTICAL CONSIDERATIONS 
 5.1. Study Design 
 The study is designed as a Phase III, rando mized, double-blind, multicenter, prospective 
comparative study of steroids + MMF vs. steroids  + placebo for treatment of acute GVHD.  The 
target enrollment is 372 patients.  5.1.1.   Accrual 
 It is estimated that three years of accrual will be necessary to enroll the targeted sample size.  Both Core and non-Core Centers will enroll patients on this study.  Accrual will be reported by 
[CONTACT_545], ethnicity, gender, and age (pediatric  patients will be defi ned as < 18 years). 
 5.1.2.  Randomization 
 Randomization will be performed in a 1:[ADDRESS_123509] ratified by [CONTACT_110892] (I-II vs. III-IV) at 
study entry.  5.1.3.  Primary Endpoint 
 The primary endpoint is the GVHD-free survival  proportion at Day [ADDRESS_123510] randomization.  The 
primary analysis will be performed using the intent-to-treat principle so that all randomized patients will be included in the analysis.  Deat h, lack of CR at Day 56, initiation of additional 
therapy, or development of chronic GVHD will be considered failures for this endpoint.  Flares 
of acute GVHD after achieving CR will not result in  a failure for the primary endpoint as long as 
the patient still achieves CR at Day 56 and does not need additional therapy.  5.1.4.  Primary Hypothesis 
 The primary null hypothesis of the study is that there is no difference between the GVHD-free 
survival proportions for MMF compared to the placebo arm.  
H
o: pMMF = p PL 
Ha: pMMF z pPL 
 
5.2. Sample Size and Power Considerations 
 GVHD-free survival at Day [ADDRESS_123511]-randomization.  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
5-2 Sample size and power considerations are ba sed on estimates from BMT CTN Protocol 0302, the 
randomized Phase II study on which this Phase III study is based.  In BMT CTN 0302, the estimated Day 56 GVHD-free survival was 71% for the MMF arm (n=44) and 47% for the three combined non-MMF arms (n=134).  Although th e observed difference in GVHD-free survival 
proportions was 24%, this was base d on a small sample size for the MMF arm.  In this study, we 
target a more modest difference of 15%, which wo uld still be considered c linically relevant.  The 
sample size of 186 patients per group, or 372 total, is sufficient to maintain type I error of 5% 
across all planned interim analyses (see below) while providing 80% statistical power for a two-
sided test to detect an increase in the GVHD-fr ee survival proportion at Day [ADDRESS_123512] (DSMB) at 
approximately six month intervals.  Monitori ng of key safety e ndpoints will be conducted 
monthly, and if rates significantly exceed pre-set thresholds, the NHLBI will be notified in order that the DSMB can be advised.  Policies and composition of the DSMB are described in the 
BMT CTN's Manual of Procedures.  5.3.1.  Interim Analysis for Efficacy and Futility 
 Analyses will be performed as described belo w for the primary endpoint.  Toxicity, adverse 
events, and other safety endpoints will be monitore d regularly and reported to the DSMB at each 
interim analysis.   At each interim analysis time point, a two-sided test to detect either an increase or decrease in the 
GVHD-free survival proportion at Day [ADDRESS_123513] statistic is outside the continuation range, the DSMB will discuss the continuation of the trial.  In order to preserve the over-all type I error ra te at 5%, efficacy and futility stoppi[INVESTIGATOR_110849] I e rror rate alpha and the type II 
error rate beta.  The error spending function defined by f( W PLQƒÆW
3ƒÆZKLFKDSSUR[LPDWHVWKH
O‚ÄôBrien-Fleming efficacy boundary , will be used for both error rates, except that stoppi[INVESTIGATOR_110850].  This error spending function approach permits necessary flexibility in the scheduling of interim analyses based on the rate of accrual and the timing of DSMB meetings.    As an example, Table 5.3a shows the critical values and cumulative error rates for tests 
conducted every six months starting with the 8
th month after the study opens to enrollment.  The 
column labeled ‚Äúfollowed to 56 days‚Äù shows th e expected number of individuals who have 
reached the 56-day post-randomization follow-up  time point, assuming uniform accrual over a 
three-year period.  The fraction of patients follo wed to 56 days, as compared to a denominator 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
5-3 comprised of the total sample of 372, quantifies the ‚Äústatistical  information‚Äù from which the 
critical values are computed.    
TABLE 5.3a ‚Äì CRITICAL VALUES 
 
Calendar 
Time 
(Months)  # of Patients 
Followed to  
56 Days  Stop for 
Futility 
 if |Z|<  Stop for 
Efficacy 
 if |Z|>  Cumulative 
Type I  
Error  Cumulative 
Type II  
Error  
8 62 - 4.30 .0002  - 
14 124 - 3.22 .0018  - 
20 186 0.28  2.86 .0062  0.0250  
26 248 0.74 2.58 .0148  0.0593  
32 310 1.38 2.30 .0289  0.1157  
38 (Final)  [ADDRESS_123514] comparing the Binomial proportions.  
These simulation results assume that the interi m analyses are conducted at equally spaced 
information times.  Also shown are the stoppi[INVESTIGATOR_110851].  This table shows that the target sample  size of 372 patients has 
>80% power to detect a 15% imp rovement in GVHD-free survival. 
 
TABLE 5.3b ‚Äì POWER TO REJECT THE NULL HYPOTHESIS  
UNDER VARIOUS SCENARIOS 
 
Proportion Alive and   Probability of Stoppi[INVESTIGATOR_110852] 
(Cumulative) GVHD-Free at Day 56 Reason for 
stoppi[INVESTIGATOR_110853] 62 124 186 248 310 372 Power 
0.47 0.47 Efficacy 0 0.002 0. 004 0.008 0.014 0.021 0.049 
    Futility 0 0 0.175 0.372 0.304 0.1   
0.47 0.52 Efficacy 0 0.005 0. 013 0.025 0.043 0.065 0.151 
    Futility 0 0 0.14 0.284 0.28 0.145   
0.47 0.57 Efficacy 0.001 0.02 0.054 0.098 0.138 0.153 0.464 
    Futility 0 0 0.068 0.13 0.18 0.157   
0.47 0.62 Efficacy 0.005 0.07 0.161 0.216 0.213 0.145 0.809 
    Futility 0 0 0.021 0.033 0.058 0.078   
0.47 0.67 Efficacy 0.014 0.18 0.306 0.263 0.151 0.056 0.969 
    Futility 0 0 0.004 0.004 0.008 0.015   
* from simulation with 100,000 replications  
 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
5-4 5.3.3.  Guidelines for Safety Monitoring 
 Monitoring of a key safety endpoint will be conduc ted monthly, and if rates significantly exceed 
pre-set thresholds, the NHLBI will be notified in order that the DSMB can be advised.  Policies and composition of the DSMB are described in  the BMT CTN's Manual of Procedures.  The 
stoppi[INVESTIGATOR_110854]. 
 The key safety endpoint for this study is mortality.  The rate of mortality will be monitored up to 
[ADDRESS_123515] be observed in order to trigger review.  Each month, the null hypothesis th at the 28-day mortality rate is less than or 
equal to 7.5% is tested.  An exte nsion of the sequential probability ratio test (SPRT) for censored 
exponential data w ill be used for monitoring, as descri bed in greater detail below and in 
Appendix D.  This sequential testing procedure conserves type I error at 5% across all of the monthly 
examinations.  The SPRT can be represented graphically.  At each monthly interim analysis, the total time on study is plotted against the total number of endpoints (e.g. , patients experiencing 
death).  The continuation region of the SPRT is defined by [CONTACT_110893].  Only the lower 
boundary will be used for monitoring to protect ag ainst excessive 28-day mortality.  If the graph 
falls below the lower boundary, the SPRT rejects the null hypothesis, and concludes that there 
are more events than predicted by [CONTACT_110894] d time on study.  Otherwise, the SPRT continues 
until enrollment reaches the maximum of [ADDRESS_123516], summed for all patients on study. 
 
The usual measures of performance of an SPRT are the error probabilities D and E of rejecting 
H
0 when T = T0 and of accepting H 1 when T = T1, respectively, and the expected sample size 
E(N|Ti).  The tests to be used in this protocol  were developed from the following SPRTs:   
x A SPRT contrasting 7.5% versus 22.5% 28-day rate of mortality re sults in decision 
boundaries with a common slope of 6.695 and a lower intercept of ‚Äì12.691, with nominal 
type I and II errors of 9% and 15%, respectively. 
 The actual operating characteristics of the truncated  test, shown in Table 5.3c, were determined 
in a simulation study that assumed uniform accr ual of 186 individuals over a three-year time 
period, and exponential time to fa ilure after randomization.   
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
5-5 TABLE 5.3c:   OPERATING CHARACTERISTICS OF SEQUENTIAL TESTING 
PROCEDURE FROM A SIMULATION STUDY WITH 10,000 REPLICATIONS 
  
Day 28 MORTALITY  
 
True 28-Day Rate 7.5% 12.5% 17.5% 
Probability Reject Null 0.052 0.449 0.929 
Mean Month Stopped 35.4 25.5 11.9 
Mean # Endpoints in 100 Days 13.3 16.0 10.3 
Mean # Patients Enrolled 178.0 129.0 61.2 
 
For example, the testing procedur e rejects the null hypothesis in fa vor of the alternative 5% of 
the time when the true 28-day mortality rate is  7.5%, and 93% of the time when the rate is 
17.5%.  This corresponds to a type I error rate of D = 0.05 and a type II error rate of E = 0.07.  
When the true 28-day mortality rate is 17.5% , on average, the DSMB will be consulted [ADDRESS_123517] ug.  The type and severity of 
adverse events will be described.  5.3.5.  Monitoring Guidelines for Dose Reduction 
 Rates of dose reduction w ill be compared between the blinde d study arms early in accrual to 
determine whether there is evidence of a differential rate.  Such a difference would indicate that the starting dose should be decreased from 3 times daily to 2 times dail y.  Dose reduction is 
defined as one week of sustained dose reduction from TID dosing through Day 28.  It is anticipated that rates of dose reduction will be  low in the placebo arm, approximately 10-20%, 
and the monitoring rule is designed to identify a 30% absolute difference in dose reduction rates 
between the two study arms with 80% power.  If th e monitoring rule is triggered, the DSMB will 
be notified and asked to review unblinded toxicity data in the two arms to assess whether the 
starting dose of MMF should be decreased.  The dose reduction stoppi[INVESTIGATOR_110855]  O‚ÄôBrien-Fleming boundary  for the Z statistic 
comparing the probabilities of dose reduction by [CONTACT_2006] [ADDRESS_123518] 75% of the patients to be treated in the same way and with the same starting dose.  Enrollment will not be put on hold after the 20
th and 40th patients are enrolled unless the 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123519] statistic is close enough to the boundary that the additional follow up could potentially 
trigger the stoppi[INVESTIGATOR_1877].    Details of the stoppi[INVESTIGATOR_110856] 5.3d.  Also contained in the table are the 
cumulative probabilities of triggering DSMB review as a function of the increase in dose reduction rates, assuming a 20% ba seline dose reduction rate in th e placebo arm.  These stoppi[INVESTIGATOR_110857] l proportions for the dose reduction rate 
in each group; in practice, the stoppi[INVESTIGATOR_110858], including those with  less than 28 days of follow-up.  The binomial 
calculation provides a conservativ e estimate of the power for this stoppi[INVESTIGATOR_1877].  The stoppi[INVESTIGATOR_110859] I error rate at 5% if there is no increase in the dose reduction rates, and has more than 80% power to identify a 30% increase in the dose reduction rates within 40 patients.  The type I error rate is still controlled and the power is higher if the baseline dose reduction rate is 10% (results not shown).   
TABLE 5.3d: MONITORING RULE AND OP ERATING CHARACTERISTICS FOR 
DOSE REDUCTION RATES IN THE FIRST 40 PATIENTS PER ARM 
 
  Cumulative stoppi[INVESTIGATOR_110860] 
# of patients 
per arm Stop if 0% 20% 25% 30% 
20 |Z|>2.80 0.006 0.114 0.200 0.298 
40 |Z|>2.05 0.050 0.512 0.677 0.822 
 
5.4. Demographic and Baseli ne Characteristics 
 Demographics and baseline characteristics will be summarized for all patients.  Characteristics to be examined are: age, gender, race/ethnicity, pe rformance status, primary disease, risk status, 
acute GVHD grade at enrollment, donor age, donor  gender, and donor ethnicity.  Between group 
comparisons will be performed for continuous variab les via a t-test and for categorical variables, 
via the chi-square test.  5.5. Analysis of Secondary Endpoints 
 5.5.1.  Proportion of CR, PR, MR , NR and Progression  
 Proportions of Complete Res ponse (CR), Partial Response (P R), Mixed Response (MR), No 
Response (NR) and Progression at Days 14, [ADDRESS_123520] for comparing binomial proportions. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123521] for comparing binomial proportions.  
This will be done both for all flares as well as fl ares that require additi onal systemic therapy.   
 5.5.4.  Immunosuppression Discontinuation 
 The incidence of discontinuation of immunosuppre ssion will be computed separately in each 
treatment group using the cumulative incidence curv e, with death prior to discontinuation as the 
competing risk.  Pointwise 95% confidence inte rvals will be provided at Day 56, Day 180, and 
Day 360.  Comparison of the cumulative incidence curves between treatment will be done using 
Gray‚Äôs test.    5.5.5.  Steroid Dose at Days [ADDRESS_123522].    5.5.6.  Incidence of Topi[INVESTIGATOR_2855]/Non-absorbable Therapy by [CONTACT_2006] 56 
 The proportion of patients using topi[INVESTIGATOR_2855]/non-absorbable thera py by [CONTACT_2006] [ADDRESS_123523] for binomial proportions. 
 5.5.7.  Chronic GVHD 
 The incidence of chronic GVHD will be computed  using the cumulative incidence estimator, 
treating death prior to chronic GVHD as a competi ng risk.  Pointwise confidence intervals will 
be provided at 6 and 12 months, and the cumulative incidence curves will be compared using Gray‚Äôs test.    5.5.8.  Overall and GVHD-free Survival 
 Overall survival will be computed using the Kaplan-Meier estimator.  Pointwise confidence intervals will be provided at Da ys [ADDRESS_123524].  GVHD -free survival will be estimated using simple 
proportions of patients alive and without GVHD if there is no censoring prior to 180 or 360 days.  
If there is censoring, the proportion of patients alive and without GVHD will be estimated in 
each treatment using multi- state model techniques.
30   
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123525] serious infection will be described using the cumulative incidence function with death as the competing risk, and compared  between treatments using Gray‚Äôs test. 
 5.5.10.  Incidence of EBV 
 The incidence of EBV-associated lymphoprolifer ative disorder or EBV reactivation therapy 
through Day 360 will be desc ribed using the cumulative inciden ce function, treating death as the 
competing risk.  Cumulative incidence curves will be compared between treatments using Gray‚Äôs test.  5.5.11.  Disease-free Survival at [ADDRESS_123526]-randomization 
 Non-relapse mortality will be estimated using the cumulative in cidence method, treating relapse 
as the competing risk.  The cumulative incidence curves for non-relapse mortality will be compared between the treatments using Gray‚Äôs test.  5.5.13.  Change in Patient-Reported Outcomes from Enrollment to Day [ADDRESS_123527] sensitive to cha nge when acute GVHD improves objectively.  
  
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
 
 APPENDIX A 
 
HUMAN SUBJECTS  
 
   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123528] consent : Candidates for the study will be identified as described in Chapter 4 of the 
protocol.  The Principal Investigat or or his/her designee at each tr ansplant center will contact [CONTACT_110895].  The st udy coordinator at each center will provide the 
patient with information about the purpose of the study and obtain consent.  The Network will 
provide a template of the consent form to each center.  Each center will customize the template according to their local requirements and submit it for review by [CONTACT_110896] 
(IRB).  The DCC will verify the adequacy of the consent forms.  Each center must provide evidence of IRB approval.    Confidentiality : Confidentiality will be maintained by [CONTACT_110897] a patient identifier code.  The code relaying the patient‚Äôs identity with the ID code will be kept separately at the center.  The ID code will be transmitted to the network.     Participation of women, children, minorities and other populations : Women, children and 
ethnic minorities will be included in this study.  Accrual will be monitored within each center w ith the expectation that the enrolled patient 
population is representative of the transplanted pa tient population at each center.  Representation 
will be examined by [CONTACT_110898], race, ethnicity and age distributions.  Accrual of minority patients will be expected to be in  proportion to the numbe r of minority patients 
transplanted at each center.  The DCC and NHLB I will discuss enrollment anomalies with the 
centers.  
  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
 APPENDIX B 
 
INFORMED CONSENTS 
AND 
EDUCATIONAL MATERIAL 
 
  
INFORMED CONSENT TO PARTICIPATE IN RESEARCH 
 
ASSENT TO PARTICIPATE IN RESEARCH 
   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-1 Informed Consent to Participate in Research 
 
 
 
 
 
 
 
 
  Your Name:             
 
[CONTACT_2759] : A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating 
Corticosteroids with Mycophenolate Mo fetil vs. Corticosteroids with Placebo 
as Initial Systemic Treatment of Acute GVHD. 
 Protocol : 0802 
 Investigator : Javier Bola√±os Meade, M.D.  
Sidney Kimmel Comprehens ive Cancer Center at Johns Hopkins  
[ADDRESS_123529] Baltimore MD [ZIP_CODE]  Phone: [PHONE_2537]. 
 Co-Investigator : Vincent T. Ho, M.D. 
Dana Farber Cancer Institute [ADDRESS_123530]  [LOCATION_011] MA [ZIP_CODE] Phone: [PHONE_2538] 
 Transplant Center Investigator :              
 
Sponsor : The National Institutes of Health (NIH) gave financial support for this 
research study through the Blood and Ma rrow Transplant Clinical Trials 
Network (BMT CTN).  
 Introduction  
You are invited to join a research study.  Th is study will evaluate a GVHD treatment that 
includes the use of prednisone (a corticosteroid ) and either: a placebo (sugar pi[INVESTIGATOR_4382]) or the study 
drug, mycophenolate mofetil (MMF).  The placebo is  not a treatment and will have no effect on 
your condition.  The placebo or MMF will be randomly assigned to you. 
 If you decide to join the study, you will receive ei ther steroids and MMF, or steroids and a 
placebo.  If you choose not to join the study, you will receive standard treatment. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123531] udy.  Please take your time 
to make your decision.   Everyone who takes part in research at  [insert facility name] should know that: 
¬É Being in any research study is voluntary. 
¬É You may or may not benefit fro m being in the study.  Knowledge we gain from this study 
may benefit others. 
¬É If you join the study, you can quit the study at any time.   
¬É If you decide to quit the study, it will not affect  your care at [insert name [CONTACT_110916]]. 
¬É Please ask the study staff questions about anything that you do not understand, or if you 
would like to have more information. 
¬É You can ask questions now or any time during the study. 
¬É Please take the time you need to talk about the study with your doctor, study staff, and 
your family and friends.  It is your decision to be in the study.  If you decide to join, please sign and date the end of the Consent Form. 
 You and your doctor will discuss other treatment choices if you do not want to participate in this study . 
  1. Background  
 This research study is sponsored by [CONTACT_110899] l Institutes of Health (NIH) through the Blood 
and Marrow Transplant Clinical Tr ials Network (BMT CTN).  The goal of this study is to find a 
better treatment for acute GVHD in people who have had an alloge neic blood stem cell 
transplant.   Acute GVHD is a medical condition that can be come very serious.  Acute GVHD is a common 
development after allogeneic stem cell transplant . It happens when the donor cells attack and 
damage your tissues after transpla nt.  Acute GVHD often causes:  
¬É Skin rashes 
¬É Nausea (feeling sick to your stomach) 
¬É Vomiting (throwing up) 
¬É Abdominal pain 
¬É Diarrhea  
¬É Liver damage that can cause inflammation in the liver or jaundice (yellowing of the skin 
or eyes)   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-3 Patients with acute GVHD are at risk to develop chronic GVHD.  Chronic GVHD may also 
cause damage to other organs.  Acute and chronic GVHD may be bad enough to cause death. 
 Corticosteroid (or steroid) medications, such as prednisone, are the standard of care for early 
treatment of GVHD.  However, le ss than half of patients will become free of acute GVHD when 
steroid treatment is used alone. Inform ation from a BMT CTN study suggests that 
Mycophenolate mofetil or ‚ÄúMMF‚Äù in combination w ith standard steroid therapy may lower the 
risk of developi[INVESTIGATOR_110861].   MMF is a drug that blocks the growth of the immune cells (T lymphocytes), which are believed 
to cause GVHD.  MMF is approved by [CONTACT_941] U.S. Food and Drug Administration (FDA) to prevent 
rejection after organ transplant .  MMF has been used for years as a treatment for GVHD that 
does not respond to standard corticosteroid ther apy, or to prevent GVHD after allogeneic stem 
cell transplant.    2. Purpose  
 You are invited to join this research study be cause you have developed acute graft-versus-host 
disease (GVHD) and your doctor feels that treatment for the GVHD is necessary.   
 We will measure how the addition of MMF compares  long-term to the standard treatment of 
steroids for acute GVHD.  Specifically, we also want to know if MMF will: 
¬É Reduce the symptoms and signs of acute GVHD, or  
¬É Eliminate acute GVHD completely.  
 
MMF will be compared to a placebo (sugar pi[INVESTIGATOR_4382]) to  learn if it will reduce or eliminate your acute 
GVHD when added to the standard  treatment of steroids.  
 We also want to collect extra blood samples a nd mouth swabs for future research on GVHD.  
You may take part in this add itional study if you want to.  You can  still be part of the main study 
even if you do not want to donate extra blood samples.   3. Right to Ask Questions and/or Withdraw  
 You have the right to ask questions about the study at any time.  If you have questions about 
your rights as a participant or you want  to leave the study, please contact:  
[insert contact [CONTACT_2997]]  Being in this study is voluntary.  You can choose to not be in this study, or leave this study at 
any time.  If you choose to not take part or to leave this study, your  regular medical care will not 
be affected in any way.  This incl udes standard care for your acute GVHD. 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123532] by [CONTACT_110900], you will need to come back to the doctor‚Äôs office for tests for your 
safety.  Even if you withdraw from the study, the information collected from your participation will be included in the study evaluation, unless you specifically ask that it not be included. 
 Your study doctor and study staff will be available to answer any questions that you may have about 
your participation in, or your withdrawal from this study.   4. Procedures  
 Before you join the study, we will ask you about your medical history, and any medications you 
may be taking.  It is important that you do not  participate in the study if you suffer from an 
allergy to  mycophenolate mofetil (MMF); or if you are pregnant, breastfeeding or are likely to 
become pregnant during the study.   Your doctor will do a number of te sts to determine if you are able to join this study.  These tests 
include: 
¬É A physical exam that also measures the stage of your GVHD. 
¬É Your ability to do regular daily activities (performance status). 
¬É Routine blood tests to check your blood count s, how well your liver and kidneys work, 
and levels of GVHD prevention medicati ons in your blood (if it applies to you). 
¬É Pregnancy test (if it applies to you). 
 If you decide to join, we will ask you to sign th is Consent Form, and you will get a copy of the 
signed form to keep.  There will be two study groups.  One group will receive MMF and the other group will receive 
the placebo.  Both groups will receive the standard  treatment of steroids .  About [ADDRESS_123533] join 
the study.  Another part of the study will ask questions about your symptoms. This information will be 
collected at two times: enrollment on the study and a pproximately 56 days later.  The survey has 
19 questions and should take less than 5 minutes to complete.  You may skip any questions you 
wish.  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123534] your safety.  Additional Study Visits and Procedures  
We will give you a placebo or MMF along with pre dnisone or methylprednisolone (steroids), 
which are standard treatment for acute GVHD.  Th e placebo and MMF come in the form of pi[INVESTIGATOR_3353]. 
If you cannot take pi[INVESTIGATOR_3353], the placebo or MMF can be given to you through your vein (IV 
infusion).    You will take your assigned dr ug three times each day for up to 8 weeks.  We will watch you 
closely for: 
¬É Signs of GVHD 
¬É Changes in your blood counts,  liver and kidney function 
¬É Any side effects 
¬É Signs of infection 
 Weekly Health Evaluations  
We will evaluate your health every week for [ADDRESS_123535] extra blood samples if you agreed to participate in the 
optional research sample portion of this study.  Each health evaluation will include tests to 
evaluate your: 
¬É GVHD stage 
¬É Ability to do daily activities (performance status) 
¬É Blood counts, liver and kidney function, and levels of GVHD prevention medications in 
your blood (if it applies to you) 
¬É Development of any side effe cts or signs of infection 
 These tests and how often they are scheduled are standard care for patients with acute GVHD 
and would be done even if you we re not part of this study. 
 Monthly Health Evaluations  
Once you finish the [ADDRESS_123536] joined the study.   During these visits, we will evaluate your: 
¬É GVHD stage 
¬É Ability to do daily activities (performance status) 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-6 ¬É Routine blood tests including your blood count s, how well your liver and kidneys work, 
and levels of GVHD prevention medicati ons in your blood (if it applies to you) 
 The evaluations at week [ADDRESS_123537] be do ne at the transplant center.  Other exams and 
tests may be done at the transplant center or at  a local doctor‚Äôs office if your condition improves 
and it is closer to where you live, at th e discretion of your transplant doctor.  
 These tests and how often they are scheduled are standard care for patients with acute GVHD 
and would be done even if you we re not part of this study. 
  5. Alternative Treatments  
 Current available treatments which may be used to treat acute GVHD include: 
¬É Corticosteroids without the study drug (standard treatment for GVHD) 
¬É Participation in another c linical trial (if available, check with your doctor) 
 Every treatment option has benefits and risks.  Your study doc tor will discuss these options with 
you.  If you decide not to participate in this rese arch study, your medical care will not be affected 
in any way.   6. Risks and Discomforts  
 
a.) Side Effects of Study Drugs 
All drugs can have side effects, including th e standard therapy for GVHD (steroids) and 
MMF being tested in this study.  Your doc tor will watch you carefu lly and will change 
your treatment if side effects develop.  MMF used in addition to steroids for GVHD is an 
experimental treatment , but information has already been collected on its effects in 
people.  We have a limited amount of informa tion about children (p ediatric patients) 
treated with MMF for GVHD.    Placebo:   The placebo will look and taste like MMF (myc ophenolate mofetil) but it is not a drug.  
The placebo is not expected to have any si de effects and it will have no effect on your 
condition.  Mycophenolate Mofetil (MMF):   MMF is a potent immunosuppressive drug that bl ocks the growth of the immune cells 
that can cause GVHD.   Risks and side effects related to MMF include those that are : 
 Common (more than 20% of patients) 
¬É Infection 
¬É Upset stomach, including nausea 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-7 Less common (less than 20% of patients)  
¬É Low blood counts  
¬É Vomiting  
¬É Diarrhea 
Rare but serious (less th an 2-3% of patients) 
¬É Serious injury to your gut (digestive tract), including bloody stools and vomit 
¬É Secondary cancers, such as lymphopr oliferative disease or lymphoma  
¬É Serious infections of the brain 
¬É Risk to a baby [CONTACT_110901]  
¬É Progressive Multifocal Le ukoencephalopathy (PML) 
 
b.) Infections 
Because GVHD is caused by [CONTACT_110902], all treatments fo r GVHD include drugs to cont rol (suppress) that immune 
attack. There is a higher risk of infecti on in patients with GVHD and any treatment for 
GVHD may also increase your risk of infecti on.  Infections may be bad enough to cause 
death.  You will need to take several antibiotics to prevent infecti on.  You will also be watched 
carefully for any infections while you are being treated for GVHD.  Tell your doctors 
promptly if you get a fever, chills, cough or a ny other symptoms that might be a sign of 
an infection.  
c.) Risks of Other Procedures Including Blood Draws   
There are no major risks associated with  drawing blood.  Having your blood drawn can 
be uncomfortable and can sometimes cause a bruise.  In rare cases, a blood draw can cause fainting.  Only trained people will draw your blood.  
d.) Reproductive Risks 
MMF may cause injury or birth defects if it is  taken during pregnancy.  Because of this, it 
is important that you are not pregnant or breast-feeding and do not become pregnant 
during the course of the study.  
If you are a woman and pregnancy is a possibilit y, you will need to take a pregnancy test 
before you start the study.  You should discuss ways to not become pregnant while you 
are participating on the study.  Unless you have been in menopause for at least [ADDRESS_123538] either use abstinence or two 
non-hormone forms of birth control (such as a condom, diaphragm, or spermicide).  You 
must continue to prevent pr egnancy before and during your treatment with MMF, and for 
at least [ADDRESS_123539] for you.  If you do become pregnant while you are in 
the study, you should tell your doctor right aw ay.  You will be removed from the study 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123540] not 
continue to take the study drug if you are pregnant. 
 
e.) Unforeseen Risks 
New risks might appear at any time during the study that are different from the risks 
listed in this Consent Form.  We will promp tly tell you of any new information that may 
affect your decision to participate.  
f.) Other Treatments or Medications  
Some medicines react with each other, and it is important that you tell the study doctor or 
staff about any other drugs, treatme nts, or medicines you are taking.   
 This includes non-prescription me dications, vitamins and herbal  treatments.  It is also 
important that you tell the study staff about a ny changes to these medications during your 
participation in the study.  
g.) Risks of completing the survey 
Completion of the survey about your sy mptoms will not cause you any physical 
discomfort, although it is possible that you will find some of the questions or topi[INVESTIGATOR_110862].  If you do, there will be someone av ailable to speak with you.  They will be 
able to refer you to appropriate counselors or other support people. 
  7. Possible Benefits  
 Taking part in this study may or may not make your h ealth better.  While doctors hope that MMF 
in combination with steroids will be more us eful against acute GVHD compared to the usual 
treatment, there is no proof of this yet.  We do know that the information from this study will 
help doctors learn more about MMF in the trea tment of acute GVHD.  This information could 
help future allogeneic transplant patients   8. New Information Available During the Study  
 During this research study, new information about the study drug or the risks and benefits of the 
study may become known to the study doctors.  If this happens, they will tell you about the new 
information.  The new information may mean that you can no long er participate in the study, or that you may not 
want to continue in the study.  If this happens, the study doctor will stop your participation in the 
study and you will be offered all available car e to suit your needs and medical conditions. 
  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123541] 
number at [insert facility name].  Information about your transplant from your origin al medical records may be seen or sent to 
national and international transplant registries, including:  
¬É The Center for International Blood and Marrow Transplant Research (CIBMTR) 
¬É The National Marrow Donor Program (NMDP) 
¬É The Food and Drug Administration (FDA) 
¬É The National Institutes of Health (NIH), whic h include the National Heart, Lung, and Blood 
Institute (NHLBI) and the National Cancer Institute (NCI) 
¬É Data and Coordinating Center of the Blood an d Marrow Transplant Clinical Trials Network 
(BMT CTN), and  
¬É Other authorized study organizations.   
 We will not identify you by [CONTACT_110903].     10. Ending Your Participation  
 The study doctor or the study sponsor may stop th e study at any time.  We may ask you to leave 
the study if you do not follow directions or if you suffer from side-effects of the treatment.  If 
you are asked to leave the study, the reasons will be discussed with you.   Possible reasons to end your par ticipation in this study include: 
¬É You do not meet the study requirements.   
¬É You need a medical treatment not allowed in this study. 
¬É The study doctor decides that it would be harmful to you to stay in the study. 
¬É You are having serious side effects. 
¬É You become pregnant. 
¬É You cannot keep appointments or take study drugs as directed. 
¬É The company making the study drug/place bo is no longer able to supply it. 
¬É The study is stopped for any reason. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123542] been hurt or 
injured because of taking part in this study.  You will get medical treatment if you are injured as a result of taking part in this study.  You and/or your  health plan will be charged for this treatment.  
This study will not pay for medical treatment.  In cas e of injury resulting from this study, you do not 
lose any of your legal rights to seek payment by [CONTACT_3368].   12. Compensation or Payment  
 You will not be paid for your participation in the research study.  You will not get compensation or 
reimbursement for any extra expenses (travel, m eals, etc.) you may have through your participation 
on this trial.   13. Costs & Reimbursements  
 Most of the visits for this research study are standard medical care for patients with GVHD and will be billed to your insurance company.  You and/or your health plan/insurance company will need to 
pay for some or all of the costs of standard treatment in this study.   
 You or your insurance will not be charged for th e study medication (MMF or placebo) or for the 
optional blood and DNA samples for research on th is study.  The study drug will be provided free 
of charge while you are participating in the study.   14. Ethical Review  
 The ethical aspects of this research study have  been reviewed and approved by [name [CONTACT_110917]]. 
  15. Further Information  
 If you need any information about this study, or if you have any problems while you are 
participating in this study you can contact [CONTACT_110904]/her staff.  They may be contact[CONTACT_110905]:  [Insert name [CONTACT_3669] [CONTACT_8972]].   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123543]:   [Insert appropriate contact [CONTACT_8972]] 
  Please note: This section of the informed Co nsent Form is about an  additional research 
study that will be done with people who are taking part in the main study.  You may take part in this additional study if you want to.  You can still be a part of the main study even if you say ‚Äòno‚Äô to take part in this additional study.  
  Blood and DNA Samples for Research  
We are asking your permission to collect and store extra blood and a DNA sample.  These 
samples will be used for future research on GVHD tests and treatment.  DNA is a molecule that contains a person‚Äôs genetic information.  We would collect a sample of your DNA by [CONTACT_2329] a 
mouth swab.  DNA from your stored blood and DNA samples and your  health information might be used in 
genome-wide association (GWA) studies for a future project either done or supported by [CONTACT_4878] (NIH).  Genome-wide association studies are a way for scientists to identify genes involved in human disease.  This  method searches the genome for small genetic 
changes that are more common in people with a particular disease than in people without the 
disease.  Each study can look at hundreds of thous ands of genetic change s at the same time.  
Researchers use data from this type of study to  find genes that may add to a person‚Äôs risk of 
developi[INVESTIGATOR_007] a certain disease.  If your coded geneti c and clinical information is used in such a 
study, the researcher is required to add the DNA test results and non-identifying information into 
a public research database.  Th is public database is called the NIH Genotype and Phenotype 
Database and it is mana ged by [CONTACT_29070] (NCBI).  The 
NCBI will never have any information that w ould identify you, or link you to your information 
or research samples.  A new federal law (2009), called the Genetic  Information Nondiscr imination Act (GINA) 
generally makes it illegal for hea lth insurance companies, group he alth plans, and employers of 
[ADDRESS_123544] 
genetic discrimination by [CONTACT_55173], disability insurance, or long-term care insurance.   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-12 Procedures  
¬É We will collect a sample of your DNA by [CONTACT_2329] 4 mouth swabs on Day 0. 
¬É We will collect blood samples at three differen t dates in the study: Pre-treatment baseline 
at Day 0, and then on Day 28 and Da y 56 after treatment begins.   
¬É The amount of blood collected from you is small ‚Äì about 2 teaspoons (10-12mL) each 
time. 
¬É These samples will be used for protocol-defined studies and may also be stored 
indefinitely for future research.  
 
Withdrawal  
If you agree to allow your blood and DNA samples to  be used for research, you can change your 
mind at any time.  If you change your mind, please contact [the Principal Investigator [INVESTIGATOR_110863]] in writing to state that you are withdrawing permission for your blood to be 
used for research.  His/her mailing address is on th e first page of this Consent Form.  Any unused 
tissue will be destroyed if you withdraw your permission.  If you choose not to participate in 
this additional resea rch there will be no change in your care . 
 Benefits  
You will not benefit direc tly from providing blood and DNA samples for this study. 
 Risks  
There are no major risks associated with drawing blood.  Having your blood drawn can be 
uncomfortable and can sometimes cause a bruise.  In rare cases, it can cause fainting.  Only 
trained people will draw your blood.  Confidentiality and Your Medical Information The results of GVHD research done with your bl ood and DNA will not be part of your medical 
record and will not be shared with you.  If you agree to allow your blood and DNA samples to be  used for research, they will be collected 
confidentially and your na me will not be on the tubes.  Only  the study doctors or staff working 
with them will study the results from your blood and DNA samples.  Information gained from research on your blood and DNA may be used to develop of diagnostic 
procedures or new treatments for GVHD in the fu ture.  Your blood will not be sold to any 
person, institution, or company fo r financial gain or profit. 
 Making Your Choice  
Please read each sentence below and think about your choice.  After reading each sentence, make 
your selection by [CONTACT_110906].  If you have any questions, please talk to your 
doctor or nurse, or call our research review board at [IRB's phone number]. 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123545] your care. 
 
¬â I agree to allow my blood and DNA to be used for future research. 
 
¬â I do not agree to allow my blood and DNA to be used for future research. 
       
Signature [CONTACT_110918] ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123546] 1 (HIPAA1) Authorization to use and 
disclose individual health information for research purposes  A. Purpose :   
As a research participant, I authorize the Principal Investigators and the researcher‚Äôs staff to use and disclose my individual health informa tion for the purpose of conducting the research 
study:  
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids with 
Mycophenolate Mofetil vs. Cortic osteroids with Placebo as In itial Systemic Treatment of 
Acute GVHD. 
 
B. Individual Health Informatio n to be Used or Disclosed  
My individual health information that may be used  or disclosed to do this research includes:  
¬É Demographic information (for exampl e: date of birth, sex, weight)  
¬É Medical history (for exampl e: diagnosis, complications with prior treatment) 
¬É Findings from physical exams 
¬É Laboratory test results obtained at the time of work up and after treatment (for example: 
blood tests, biopsy results)  
 
C. Parties Who May Disclose My Individual Health Information   
The researcher and the researcher‚Äôs staff may collect my individual health information from: (List hospi[INVESTIGATOR_600], clinics or provi ders from which health care information can be requested). 
 D. Parties Who May Receive or Use My Individual Health Information  
The individual health information disclosed by [CONTACT_29085] c and information disclosed by [CONTACT_110907]:  ¬É Principal Investigator [INVESTIGATOR_29062]‚Äôs staff 
[CONTACT_110923] Bola√±os Meade, Principal Investigator  
[INVESTIGATOR_124]. Vincent T. Ho, Co-Principal Investigator  
¬É National Heart, Lung, and Blood Institute ( NHLBI) and the National Cancer Institute 
(NCI), both of the National Institutes of Health (NIH)  
¬É Study sponsors  
Blood and Marrow Transplant Clinical Tr ials Network (BMT  CTN), data and 
coordinating center 
 ¬É U.S. government agencies that are responsib le for overseeing research such as the Food 
and Drug Administration (FDA) and the Office  of Human Research Protections (OHRP) 
 
 
[ADDRESS_123547] of 1996, a federal law related to privacy of health 
information  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-15 ¬É U.S. government agencies that are responsible  for overseeing public health concerns such 
as the Centers for Disease Control (CDC) and fe deral, state and local health departments. 
E. Right to Refuse to Si gn this Authorization  
I do not have to sign this Authorization.  If I decide not to sign the Authorization, I will not 
be allowed to participate in th is study or receive any treatment related to research that is 
provided through the study.  My decision not to sign this authorization will not affect any 
other treatment, payment, or enrollment in health plans or eligibility for benefits.   
F. Right to Revoke   
I can change my mind and withdraw this authorization at any time by [CONTACT_5583] a written notice to the Principal Investigator [INVESTIGATOR_98364]. If I withdraw this authorization, the researcher may only use and disclose the protected health information 
already collected for this research study.  No further health information about me will be 
collected by [CONTACT_98411].  
G. Potential for Re-disclosure   
My individual health information disclosed unde r this authorization may be subject to re-
disclosure outside the research study and no longer protected. Examples include potential 
disclosures for law enforcement purposes, mandat ed reporting or abuse or  neglect, judicial 
proceedings, health oversight activ ities and public health measures. 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Informed Consent Form  Initials _____________ 
B-[ADDRESS_123548] an expi[INVESTIGATOR_320].  
  TITLE: A Multi-Center, Randomized, Double B lind, Phase III Trial Evaluating 
Corticosteroids with Mycophenolate Mofe til vs. Corticosteroids with Placebo as 
Initial Systemic Treatment of Acute GVHD  
 
I have read and understood this Consent Form.  The nature and purpose of the research study has 
been explained to me.  I understand that I will be given a copy of this signed Consent Form 
        
Participant Name [CONTACT_110919]  
   I certify that I have provided a verbal explanati on of the details of the research study, including 
the procedures and risks.  I believe the pa rticipant has understood th e information provided. 
        
Counseling Physician Date  
        
Signature [CONTACT_110920] ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Assent Form  Initials _____________ 
B-17 Assent to Participate in Research 
 
 
 
 
 
 
 
 
 Study Title : A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating 
Corticosteroids with Mycophenolate Mofe til vs. Corticosteroids with Placebo as 
Initial Systemic Treatment of Acute GVHD 
 Protocol : 0802 
  A. Why am I here? 
We are inviting you to join our study because you have acute graft-versus-host disease 
(GVHD).  We want to learn if a new drug works better than the current drug we use to treat 
GHVD.  GVHD happens when your donor cells from your transplant attack parts of the body like 
your skin, stomach or liver.  Both kids and adu lts can get GVHD.  It can be a very serious 
problem for some people.   
B. Why are you doing this study? 
We are doing this study because we want to lear n if a single drug or a combination of drugs 
work better to get rid of gr aft-versus-host disease (GVHD). 
¬É Prednisone with a sugar pi[INVESTIGATOR_4382] (placebo) or 
¬É Prednisone with MMF  (mycophenate mofetil) . 
  
C. What will happen to me? 
If you say you want to be in the study, we will ask you for several things: 
¬É Permission to let us read your medical records and x-rays.  
¬É Check-ups with the study doctors.  
¬É Some blood from you (about 12 teaspoons).  A ve ry small needle will be used to get 
blood.  
¬É We may also need a small pi[INVESTIGATOR_13959] (biopsy) of  your skin, so we can study changes in 
your skin.  If you agree to this, we will use numbing medicine before we take a small 
pi[INVESTIGATOR_110864] a special tool called a ‚Äúpunch.‚Äù 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Assent Form  Initials _____________ 
B-18  
Everyone in the study wi ll take prednisone. 
 You will also take MMF or sugar pi[INVESTIGATOR_3353] (place bos).  The doctors use a computer to choose 
which one. You will not know whic h drug you will take.  The computer will keep it a secret 
from everyone, including the study doctors.  If you get very sick, your study doctors can find 
out from the computer which drugs you take.  You will take the MMF or sugar pi[INVESTIGATOR_3353] [ADDRESS_123549] to swallow, the doctors can use a small needle to  give it through your vein (IV) or your central 
line.  Once you finish taking the drugs, you will have ab out 4 more check-ups with either the study 
doctors or your regular doctor over the next 12 months.    We will watch you carefully for fevers, any sign of infection or other problems. 
  
D. Will it hurt? 
When you have your blood taken with a needle, it may feel like a pi[INVESTIGATOR_820].  It will hurt for a 
minute and sometimes the place where the needle went might be red a nd sore. You might get 
a little bruise where the blood was take n but it goes away in a few days. 
 If you have a skin biopsy, the numbing medicine  burns when it goes in, but only for a few 
seconds.  When the numbing medicine wears off, there may be some mild pain.  It will leave 
a small scar.   
E. Will the study help me? 
We don‚Äôt know if the study will help you or not .  Your GVHD may stay the same, it may get 
better, or it may get worse.   
F. What if I have questions? 
You can ask any questions that you have about the study.  If you forget to ask a question and 
think of it later, you can call me [insert office number].  You can also ask your question the 
next time you see me.  You can call the study office at any time to ask questions about the study.   
G. Do I have to be in this study? 
If you don‚Äôt want to be in the study, you need to tell us and your parent or guardian.  Your 
doctor will not be angry or upset  if you don‚Äôt want to join.   
 Whether you are in the study or not, you will s till need to have treatment for your GVHD. 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
Information & Assent Form  Initials _____________ 
B-[ADDRESS_123550] for G VHD.  Some of your blood and a sample of cells 
from inside your cheek (DNA) will be saved for future studies.  To be in the study, you must 
agree to have your blood used for GVHD and other regular tests but you do not have to agree to 
have your blood or cheek cells (DNA) used in future studies.  Please check one of the boxes below to show  how you want your blood and cheek cells (DNA) 
to be used. 
 ¬à Yes, you may use my blood and cheek cell (DNA) samples for this study and future 
studies of GVHD. 
¬à No, you may not use my blood a nd cheek cell (DNA) samples. 
 
Writing your name [CONTACT_110921], and know what will 
happen to you.  If you decide to quit the study, a ll you have to do is tell the person in charge. 
 You and your parent or guardian will ge t a copy of this form after you sign it. 
                
Signature [CONTACT_110922] ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
 APPENDIX C 
 
LABORATORY PROCEDURES 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123551]-treatment time points as specified below. 
¬æ Peripheral Blood Sample (Pre-treatment: Day 0)  ‚Äì Whole Blood, Plasma 
¬æ Buccal Swab Samples (Pre-treatment: Day 0) ‚Äì Patient DNA  
¬æ Peripheral Blood Samples (Post-treatment:  Day 28, and 56) ‚ÄìPlasma 
 Samples processed into frozen cryovial aliquots will be shipped to the BMT CTN Repository on 
an annual basis in compliance with the shippi[INVESTIGATOR_110865] [ADDRESS_123552] labora tory and analyzed for a 4-protein biomarker 
panel.  The results from previous discovery and validation studies suggested that the panel of 
four biomarkers can confirm the diagnosis of aG VHD in patients at onset of clinical symptoms 
of aGVHD and provide prognostic information independent of a GVHD severity.  The plasma 
protein biomarker panel will include at minimum:  interleukin-2-receptor-alpha, tumor-necrosis-
factor-receptor-1, interleukin-8, and hepatocyte growth factor (recent data would support the 
addition of elafin/trappin-2 to this  panel).  Test panel and project laboratory to be finalized by [CONTACT_110908]-going study reviews are complete d and results discussed with 
principal investigators.  Donor chimerism results recorded at the time nearest to each sample 
collection will be noted.  Future GVHD Studies Remaining Day [ADDRESS_123553] ored along with additional Day 
56 plasma sample aliquots for future GVHD-rela ted biomarker studies.  Additionally, whole 
blood collected from the patient on Day 0 (rep resenting essentially donor DNA) and buccal 
swabs for DNA from the patient will be collected, frozen and stored for future GVHD-related biomarker studies.  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
C-2 TABLE C-1: COLLECTION AND SHIPPI [INVESTIGATOR_110866]-DEFINED 
BIOMARKER TESTING AND FOR FUTURE, UNDEFINED RESEARCH 
  
TIME 
POINTS COLLECTION 
OF SAMPLE TYPE OF PROCESSING 
AND STORAGE SPECIMEN 
TO BE 
SHIPPED PURPOSE 
OF 
SAMPLE SHIPPI[INVESTIGATOR_110867] 0 6 mL peripheral 
blood (one 6 mL 
fill EDTA 
lavender-top tube) 
Source of Donor 
DNA Gently mix one of the 6 ml pre-
treatment blood tubes by [CONTACT_110909] 60 seconds.  
Pi[INVESTIGATOR_8462] a 1.0 mL  aliquot of the 
whole blood into each of 6 cryovials 
and freeze at -70¬∫C in a scientific 
grade freezer. Whole 
Blood 
 Future 
GVHD 
Studies Batch ship yearly, frozen on 
dry ice in a provided shippi[INVESTIGATOR_34919], FedEx priority 
overnight to the BMT CTN 
Repository. 
6 mL peripheral 
blood (one 6 mL 
fill EDTA 
lavender-top tube) 
 Centrifuge the EDTA containing 
whole blood samples at 1000-1300 
x g or 2100 rpm for 10 minutes 
within 60 minutes of collection.  
Remove the separated plasma.  
Transfer »ù/  aliquots to 4-6 
cryovials and freeze at -70¬∫C in a 
scientific grade freezer. Plasma 
 Future 
GVHD 
Studies/4-
protein 
biomarker 
panel Batch ship yearly, frozen on 
dry ice in a provided shippi[INVESTIGATOR_34919], FedEx priority 
overnight to the BMT CTN 
Repository. 
[ADDRESS_123554] the inside of 
your cheek for approximately 10 
seconds.  Use the same force used 
to brush your teeth. Use one swab 
per section (quadrant) of your 
cheek. The 4 swabs should be dried 
for a minimum of 2 hours  before 
they are processed for long-term 
frozen storage. 
 
Each dried swab is placed into a 
separate cryovial. Cut the stick so 
that the cotton swab tip fits well 
within the cryovial. Secure the 
cryovial cap and freeze at -70¬∫C in a 
scientific grade freezer. 
 Cheek Swab Future 
GVHD 
Studies Batch ship yearly, frozen on 
dry ice in a provided shippi[INVESTIGATOR_34919], FedEx priority 
overnight to the BMT CTN 
Repository. 
Day 28 
 10 mL peripheral 
blood (one 10 mL 
fill EDTA 
lavender-top tube) 
 Centrifuge the EDTA containing 
whole blood samples at 1000-1300 
x g or 2100 rpm for 10 minutes 
within 60 minutes of collection.  
Remove the separated plasma.  
Transfer »ù/  aliquots to 6-10 
cryovials and freeze at -70¬∫C in a 
scientific grade freezer. Plasma Future 
GVHD 
Studies/4-
protein 
biomarker Batch ship yearly, frozen on 
dry ice in a provided 
shippi[INVESTIGATOR_7788], FedEx 
priority overnight to the 
BMT CTN Repository. 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
C-3 TIME 
POINTS COLLECTION 
OF SAMPLE TYPE OF PROCESSING 
AND STORAGE SPECIMEN 
TO BE 
SHIPPED PURPOSE 
OF 
SAMPLE SHIPPI[INVESTIGATOR_110867] 56 10 mL peripheral 
blood (one 10 mL 
fill EDTA 
lavender-top tube) 
 Centrifuge the EDTA containing 
whole blood samples at 1000-1300 
x g or 2100 rpm for 10 minutes 
within 60 minutes of collection.  
Remove the separated plasma.  
Transfer »ù/  aliquots to 6-10 
cryovials and freeze at -70¬∫C in a 
scientific grade freezer. Plasma Future 
GVHD 
Studies Batch ship yearly, frozen on 
dry ice in a provided shippi[INVESTIGATOR_34919], FedEx priority 
overnight to the BMT CTN 
Repository. 
 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123555] STATISTIC FOR 
CENSORED EXPONENTIAL DATA 
  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123556] STATISTIC FOR CENSORED 
EXPONENTIAL DATA 
  Background ‚Äì The Sequential Probability Ratio Test  Let 
)(.,Tf be the density function for random variable  X.  According to Neyman and Pearson, 
the most powerful test of o HTT :0  versus1 1:TT H  decides in favor of 1H or 0Hif Dc Ln! or 
Dc Ln, respectively, where ¬ñ n
ii i n xf xf L );(/);([ADDRESS_123557] the size D.  When the sample size is not fixed in advance, further 
improvement is possible by [CONTACT_110910]‚Äôs Sequential Probability Ratio Test (SPRT).  The SPRT 
continues to sample as long as A LBn  for some constant A B[ADDRESS_123558]!, and stops sampling and decides in favor of 0Has soon 
as B Ln. 
 
The usual measures of performance of such a procedure are the error probabilities DandEof 
rejecting 0Hwhen 0TT , and of accepting 0Hwhen 1TT , respectively, and the expected 
sample size )( )|( NE NEj j{T .  Wald and Wolfowitz showed that  among all tests,  sequential or 
not, for which Dd) reject (Pr0 0 H  and Ed) reject (Pr0 1 H , and for which )(NEj  are finite, j=0,1, 
the SPRT with error probabilities D and Eminimizes )(0NE  and )(1NE .  If, in addition, the 
,...2,1xx  are independent and identically dist ributed (i.i.d.) with density function ),(Txf , with 
monotone likelihood ratio in )(xW, then any SPRT for testing 0Tagainst ) (0 1TT!  has non-
decreasing power function. 
 For the SPRT with error probabilities 
DandE, the SPRT boundaries are given approximately by 
[CONTACT_34479]/) 1( A  and ) 1/(DE B .  The operating characteristics of the SPRT are given by 
) /()1 (),,,,()( )( )(
1 0T T TTTEDTh h hB A A O    where )(This the non-trivial solution to the equation 
¬≥ 1 );( )),(/);(()(
2 1 dxxf xf xfhT TTT.   
 
The formula );(/] log)( log)]( 1[[();( T T T T zEB OA O NE   provides the average sample number 
for an arbitrary T.  The sample size distribu tion is very highly skewed, 2)]([)( NE N Var| .  Thus 
we will consider a truncated test with maximum sample size of 0N and simulate to obtain the 
operating characteristics of the test. 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123559] for the composite null hypothesis that the rate 
of treatment-related mortality (TRM) at 100 days  is less than or equal to 30% versus the 
alternative hypothesis that it is greater than or equal to 50%.  For the derivation of the 
uncensored SPRT, we will require that the type I e rror of the test be less than 5%, and that the 
test provide 80% power to reject the null hypothe sis under a specified alte rnative that the true 
rate is 50%.  A maximum sample size of 50 patients will be permitted.  Let us assume that the survival times, 
nT TT ,...,,2 1 , are completely observed (uncensored) and are 
i.i.d. with exponentia l density function Te TfTTT ),( .  These assumptions will be relaxed to 
incompletely observed data s ubsequently.  In the exponen tial parameterization, a 100-day 
survival rate of 70% translates in to a mean survival of 0.768 years (  0T1.303), and 50% 
translates into a mean survival of 0.395 years (  1T2.532). 
 
The SPRT is derived with reference to a simple  null and alternative hypot hesis, in this case, 
  o HTT:0  1.303 versus1 1:TT H  = 2.532.  However, since the log-likelihood ratio for the 
exponential, ¬ñ¬ñ ¬¶  n
in
in
ii i i T n xf xf ) ()) log() (log( ),( log);( log0 1 0 1 0 1 TTTT T T , is a 
monotone function of ¬¶n
iiT, the power of the test is non-decreasing in T.  Thus the SPRT is a 
one-sided level .[ADDRESS_123560] of a composite null ( 303.1 :0 do HTT ) versus a composite alternative 
( 303.1 :1 to HTT ), with power of 80. 1 E  at the selected alternative   1TT 2.532. 
 
The SPRT can be represented graphically.  Th e continuation region is bounded by [CONTACT_110911]    ) /() log (log1 0 1 0 TTTT 0.541, and intercepts  ) /( log1 0TTA -2.256 
and  ) /( log1 0TTB 1.270, for the lower and upper bounds, respectively.  As each individual unit 
is put on trial and observed to fail, the cumulative sum of failure times, ¬¶n
iiT, is recomputed, and 
plotted against the current sample size, n.  When this graph crosses the lower boundary, the null 
hypothesis is rejected. 
 The maximum sample size of [ADDRESS_123561] 
the null at a sample size of 50 is negligible , it makes little differenc e how the final boundary 
value is selected, and this rule is chosen for simplicity.    
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123562] a 
clinical study by [CONTACT_110912], and waiting until that individual is observed to 
fail.  We relax our assumptions as follows.  Firstly, each individual‚Äôs time on study will be 
computed as time from transplant to failure, or to the [ADDRESS_123563] of relaxing these assumptions one at a time.  In a fixed sample size 
trial with uncensored exponential failure times, mean survival time is estimated by [CONTACT_110913], or total time on study divided by [CONTACT_110914].  
When censoring is introduced, the estimate becomes the total time on study divided by [CONTACT_110915] (non-censored) failures.  Th is suggests that in an  exponential SPRT test 
modified to incorporate censoring, we  replace the observed failure times, 
nT TT ,...,,[ADDRESS_123564] patient is entere d.  Putting all of this together, we propose a modified truncated 
SPRT, where at any interim time point, s, ranging from 0 to 3 years 100 days, the sum of 
observed time on study, ¬¶n
iisX)(is plotted against the number of observed failures, )(sd.  In 
practice, monitoring will be scheduled monthly after the start of enrollment to the study.  A 
further modification to the SPRT was to onl y use the lower boundary for stoppi[INVESTIGATOR_110868] 100-day TRM rates. 
 
Operating Characteristics of the Modified SPRT Test for Censored Exponential Data  
Recall that the uncensored SPRT targeted a drop in  survival at Day 100 from 70% to 50%, with 
type I and II errors of 5% and 20%.  Since only the lower boundary is used for monitoring, the 
continuation region of the test  was bounded below by a line with a slope of 0.541 and intercept 
of ‚Äì2.256.  The effect of truncation is to reduce the power of the test.  In order to compensate for 
this, we raise the lower boundary to make it easie r to cross.  Under the further assumption of 
uniform accrual over a three year period, and mont hly interim analyses over the course of the 
study, the operating characteristics of the modified  SPRT were obtained from a simulation study.  
These simulation show that an intercept of ‚Äì1.741, corresponding to  setting parameters 
D and 
Eto 10% and 15%, result in empi[INVESTIGATOR_110869] I a nd II error rates of  about 5% and 20%.   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
D-4  
Table D-1   Operating Characteristics of  Sequential Testing Procedures from a 
Simulation Study with 100,000 Replications 
 
Treatment-Related Mortality (TRM) 
True 100-Day Rate 30%  35% 40% 45% 50% 
Probability Reject Null 0.07 0.20 0.41 0.66 0.86 
Mean Month Stopped 34.5 32.3 28.5 23.5 18.5 
Mean # Endpoints in 100 Days 13.8 15.0 15.1 14.0 12.1 
Mean # Patients Enrolled 48 45 40 33 26 
 
While the motivation for this testing procedure is largely heuristic rather than theoretical, the 
simulation results validate the approach.  When the true rate of TRM on or before Day 100 was 
30%, the test crossed the lower boundary in 7119 of 100,000 replications, for an estimated type I 
error rate of 7%.  When the true rate of TRM on or before Day 100 was 50%, the test failed to 
cross the boundary in [ZIP_CODE] of 100,000 replications, fo r an estimated type II error rate of 14%.  
And on average, the boundary will be crossed at  18.[ADDRESS_123565] udies to demonstrate this. 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
E-5 APPENDIX E 
 
M.D. ANDERSON SYMPTOM INVENTORY (MDASI) 
 CORE ITEMS 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
E-1 
 
 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
E-2 
 
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol 0802 
Version 3.0 dated January 31, 2011 
 
 
 APPENDIX F 
 
REFERENCES 
   
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123566] disease. Clinical Advances in 
Hematology & Oncology 2004; 2(10):672-682.  
2 Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109(10):4119-4126.  
[ADDRESS_123567] disease. Br J Haematol 2007; 137(2):87-
98. 
[ADDRESS_123568] disease:  comparison of grading systems. Biol Blood 
Marrow Transplant 2002; 8(7):387-394.  
[ADDRESS_123569] disease: initial trea tment. Blood 1990; 76(8):1464-1472.  
[ADDRESS_123570] disease 
with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transpla ntation. Blood 1998; 92(7):2288-2293.
 
[ADDRESS_123571] disease following unrelated 
donor marrow transplantation: fa ilure of conventional therapy. Bone Marrow Transplant 1992; 
10(1):77-82  
8 Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host 
disease after allogeneic bone marro w transplantation: an analysis of clinical risk features and 
outcome. Blood 1990; 75(4):1024-1030.  
[ADDRESS_123572] 
disease. Current Opi[INVESTIGATOR_110870] 2005; 12(1):40-44.  
[ADDRESS_123573] disease with 
prednisolone: significant surviv al advantage for day +5 re sponders and no advantage for 
nonresponders receiving anti-thymoc yte globulin. Blood 2006; 107(10):4177-4181.  
[ADDRESS_123574] disease: pr edictors of response and survival. Ann Hematol 
1997; 75(1-2):41-46.  
[ADDRESS_123575] disease 
with low dose-alternate day anti-thymoc yte globulin. Haematol ogica 2002; 87(9):973-978.  
13 Cragg L, Blazar BR, Defor T et al. A ra ndomized trial comparing prednisone with 
antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Bl ood Marrow Transplant 2000; 6(4A):441-447.
 
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123576] di sease: results of a randomized trial. Blood 2004; 
104(5):1559-1564.  
[ADDRESS_123577] disease with 
methylprednisolone and cyclosporine with or  without an anti-interleukin-2 receptor 
monoclonal antibody. A multicenter phase III study. Transplantation 1995; 60(9):939-942.  
[ADDRESS_123578] disease after allogeneic marrow transplantation. Blood 
1996; 88(3):824-830.  
[ADDRESS_123579] disease. Biol Blood 
Marrow Transplant 2005; 11(9):680-687.  
18 Alousi A, Weisdorf DJ, Logan BR et al. BM T CTN 0302: A phase II randomized study trial 
evaluating etanercept, mycophenol ate mofetil (MMF), denileukin diftitox, and pentostatin in 
combination with corticosteroid s in 180 patients (pts) with newly diagnosed acute graft vs. 
host disease (aGVHD). Blood 2008; 112(11):Abstract 55.  
19 Basara N, Blau WI, Kiehl MG et al. Effica cy and safety of myc ophenolate mofetil for the 
treatment of acute and chronic GVHD in bone marro w transplant recipi[INVESTIGATOR_841]. Transplant Proc 
1998; 30(8):4087-4089.  
20 Basara N, Kiehl MG, Blau W et al. Mycophe nolate Mofetil in the treatment of acute and 
chronic GVHD in hematopoietic stem cell transplant patients:  four years of experience. 
Transplant Proc 2001; 33(3):2121-2123.  
[ADDRESS_123580] disease. Ann 
Hematol 2005; 84(10):681-685.  
[ADDRESS_123581] disease. Int J 
Hematol 2006; 83(1):80-85.  
23 McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell tr ansplantation in older 
patients with hematologic malignancies: repl acing high-dose cytotoxic therapy with graft-
versus-tumor effects. Blood 2001; 97(11):3390-3400.  
[ADDRESS_123582] em-cell transplant ations conditioned 
with fludarabine and low-dose total body irra diation. Biol Blood Marrow Transplant 2006; 
12(2):217-225.  
[ADDRESS_123583] blood transplantation 
after reduced-intensity conditioning. Blood 2003; 102(5):1915-1919.  
BMT CLINICAL TRIALS NETWORK  Acute GVHD Treatment ‚Äì Protocol [ADDRESS_123584] S, Villemain F, Lavaud S, et al.  Individualized 
mycophenolate mofetil dosing ba sed on drug exposure significa ntly improves patient out-
comes after renal transplantati on.  Am J Transplant 2007: 7:2496-2503. 
27 Gaston R, Kaplan B, Meier-Kriesche H-U, Shaw L, Shah T, Patel D, et al.  Opticept Trial: 
efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 12 months.  Am J Transplant 2008; 8(Suppl 2):319. 
[ADDRESS_123585] 
disease. Blood 2008.  
29 Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the 
M.D. Anderson Symptom Inve ntory. Cancer. 2000;89:1634-[ADDRESS_123586], Keiding N. Statistical models base d on counting processes. 
[LOCATION_001]: Springer-Verlag, 1993.  